var title_f0_38_608="Nailfold capillaroscopy in SSc";
var content_f0_38_608=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F72422&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F72422&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nailfold capillaroscopy in systemic sclerosis (scleroderma)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 263px; height: 503px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Findings on nailfold capillaroscopy in scleroderma (25x magnification).",
"    <br>",
"     (Top panel) Normal capillary pattern with parallel, evenly spaced, thin capillary loops. (25x magnification).",
"     <br>",
"      (Middle panel) Abnormal capillaroscopy in a patient with scleroderma. The few capillaries are dilated and irregularly distributed. Much of the proximal nail fold has lost its normal complement of capillaries, leaving large, white avascular areas.",
"      <br>",
"       (Bottom panel) More advanced changes in scleroderma. The few remaining capillaries have taken on a bushy configuration, and the proximal nailfold again has large avascular areas. The bushy capillary configuration is more common in dermatomyositis.",
"       <div class=\"footnotes\">",
"       </div>",
"       <div class=\"reference\">",
"        Reproduced with permission from: Richard D Sontheimer, MD. In: Resource Materials in Rheumatology, number 19: Nail changes in rheumatic diseases.",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_38_608=[""].join("\n");
var outline_f0_38_608=null;
var title_f0_38_609="Nomenclature nevi";
var content_f0_38_609=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F65457&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F65457&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 593px\">",
"   <div class=\"ttl\">",
"    Nomenclature for acquired melanocytic nevi",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 573px; height: 411px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The names applied to acquired nevi reflect the location of the nests of melanocytes (asterisks above). In junctional nevi, nests are at the dermal-epidermal junction (DEJ); in dermal nevi, nests are in the dermis, and in compound nevi, nests are at the dermal-epidermal junction and in the dermis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jean L Bolognia, MD, and Julie V Schaffer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_38_609=[""].join("\n");
var outline_f0_38_609=null;
var title_f0_38_610="Curved and Straight Halstead mosquito forceps";
var content_f0_38_610=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F73787&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F73787&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Halstead mosquito forceps",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 420px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_38_610=[""].join("\n");
var outline_f0_38_610=null;
var title_f0_38_611="Photo birth 1";
var content_f0_38_611=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F51141&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F51141&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Delivery sequence from crowning through birth of the newborn",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 295px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Early crowning of the fetal head. Notice the bulging of the perineum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wolters Kluwer. Copyright &copy;2009.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_38_611=[""].join("\n");
var outline_f0_38_611=null;
var title_f0_38_612="Desonide: Patient drug information";
var content_f0_38_612=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Desonide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13828?source=see_link\">",
"     see \"Desonide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F157907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Desonate&reg;;",
"     </li>",
"     <li>",
"      DesOwen&reg;;",
"     </li>",
"     <li>",
"      LoKara&trade;;",
"     </li>",
"     <li>",
"      Verdeso&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F157908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Desocort&reg;;",
"     </li>",
"     <li>",
"      PMS-Desonide;",
"     </li>",
"     <li>",
"      Tridesilon;",
"     </li>",
"     <li>",
"      Verdeso&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat skin rashes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701911",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to desonide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698659",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired, weak, or touchy; trembling; having a fast heartbeat, confusion, sweating, or dizziness if you missed a dose or recently stopped this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695620",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake aerosol well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695627",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake lotion well before use.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10012048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10012053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11619 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-115.66.252.144-FC8D04C3D0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_38_612=[""].join("\n");
var outline_f0_38_612=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157907\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157908\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012045\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012044\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012049\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012050\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012052\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012047\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012048\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012053\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012054\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13828?source=related_link\">",
"      Desonide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_38_613="Guaifenesin and phenylephrine: Patient drug information";
var content_f0_38_613=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Guaifenesin and phenylephrine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/63/26612?source=see_link\">",
"     see \"Guaifenesin and phenylephrine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F177771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ambi 10PEH/400GFN [OTC];",
"     </li>",
"     <li>",
"      Fenesin PE IR;",
"     </li>",
"     <li>",
"      J-Max [OTC];",
"     </li>",
"     <li>",
"      Liquibid&reg; D-R [OTC];",
"     </li>",
"     <li>",
"      Liquibid&reg; PD-R [OTC];",
"     </li>",
"     <li>",
"      Medent&reg;-PEI [OTC];",
"     </li>",
"     <li>",
"      Mucinex&reg; Cold [OTC];",
"     </li>",
"     <li>",
"      Mucus Relief Sinus [OTC];",
"     </li>",
"     <li>",
"      Nu-COPD [OTC];",
"     </li>",
"     <li>",
"      OneTab&trade; Congestion &amp; Cold [OTC];",
"     </li>",
"     <li>",
"      Refenesen&trade; PE [OTC];",
"     </li>",
"     <li>",
"      Rescon GG [OTC];",
"     </li>",
"     <li>",
"      Sudafed PE&reg; Non-Drying Sinus [OTC];",
"     </li>",
"     <li>",
"      Triaminic&reg; Children's Chest &amp; Nasal Congestion [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10021320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10021322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691980",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat nose stuffiness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691653",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to thin mucous so it can be taken from the body by coughing.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10021321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702223",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to guaifenesin, phenylephrine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705195",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Very bad heart disease or very high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10021326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697679",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is not for coughs due to smoking or lung disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697225",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man with problems passing urine, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10021327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10021329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10021324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695803",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take tablets with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting products: Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10021325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10021330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10021331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12523 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-122.72.76.133-BCBD45DDC8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_38_613=[""].join("\n");
var outline_f0_38_613=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177771\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021320\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021322\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021321\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021326\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021327\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021329\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021324\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021325\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021330\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021331\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/63/26612?source=related_link\">",
"      Guaifenesin and phenylephrine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_38_614="Vigabatrin: Patient drug information";
var content_f0_38_614=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Vigabatrin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/8/27783?source=see_link\">",
"     see \"Vigabatrin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/27/25015?source=see_link\">",
"     see \"Vigabatrin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8107369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Sabril&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F234016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Sabril&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10029394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700748",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause lasting eyesight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700639",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Only U.S. patients in the SHARE Program may get this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10029396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691482",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or control seizures.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10029395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703128",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to vigabatrin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10029400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697168",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have anemia, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697217",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have eye problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698500",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam every 3 months.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696966",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow laws about driving with a seizure problem.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10029401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698036",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Emotional ups and downs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697935",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shakiness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10029403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698512",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If seizures are worse or not the same after starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10029398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694667",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Melt the powder in 2 teaspoons (10 mL) of water and drink it right away.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10029399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10029404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10029405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12015 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-5088ACF45B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_38_614=[""].join("\n");
var outline_f0_38_614=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8107369\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234016\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029394\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029396\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029395\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029400\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029401\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029403\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029398\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029399\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029404\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029405\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/8/27783?source=related_link\">",
"      Vigabatrin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/27/25015?source=related_link\">",
"      Vigabatrin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_38_615="Monitoring and surveillance of hemodialysis arteriovenous grafts to prevent thrombosis";
var content_f0_38_615=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Monitoring and surveillance of hemodialysis arteriovenous grafts to prevent thrombosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/38/615/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/38/615/contributors\">",
"     Michael Allon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/38/615/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/38/615/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/38/615/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/38/615/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/38/615/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemodialysis requires access to blood vessels capable of providing rapid extracorporeal blood flow. These requirements are currently best met by both primary arteriovenous (AV) fistulas and synthetic grafts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/16/23816?source=see_link\">",
"     \"Arteriovenous fistulas and grafts for chronic hemodialysis access\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues surrounding monitoring and surveillance of hemodialysis AV grafts in the attempt to prevent thrombosis and graft failure are presented in this topic review. Similar issues for hemodialysis AV fistulas are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/50/27429?source=see_link\">",
"     \"Monitoring and surveillance of hemodialysis arteriovenous fistulas to prevent thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROSPECTIVE MONITORING AND SURVEILLANCE FOR STENOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Greater than 90 percent of thrombosed grafts have a stenotic lesion, suggesting that such an anatomic abnormality is required for graft thrombosis. Direct visualization of the vascular access using angiography is the gold standard to diagnosing stenosis.",
"   </p>",
"   <p>",
"    However, noninvasive assessment is preferred for efficient screening to first identify those grafts most likely to be stenotic. Only those grafts with sufficiently abnormal tests would then require diagnostic angiography and, if indicated, preemptive angioplasty.",
"   </p>",
"   <p>",
"    Currently, assessment of hemodialysis AV grafts for stenosis is performed by both clinical monitoring and noninvasive surveillance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Clinical monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical monitoring refers to assessments that can be performed by physical examination of the access or by using readily available information that is collected in the course of treating dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/615/abstract/1\">",
"     1",
"    </a>",
"    ]. A number of prospective studies have generally observed a hemodynamically significant (&gt;50 percent) stenosis in approximately 70 to 90 percent of patients with abnormalities of clinical monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/615/abstract/2-7\">",
"     2-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical monitoring falls into the following three broad categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abnormalities of physical examination, such as absent thrill, discontinuous bruit, or edema distal to the graft. In one prospective study, an abnormality of physical examination had an 80 percent positive predictive value for significant graft stenosis [",
"      <a class=\"abstract\" href=\"UTD.htm?0/38/615/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Problems noted during the dialysis session, such as difficulty with cannulation, aspiration of clots, inability to achieve the target dialysis blood flow, or prolonged bleeding from the needle puncture sites. In one prospective study, an abnormality noted during the dialysis session had a 66 percent positive predictive value for significant graft stenosis [",
"      <a class=\"abstract\" href=\"UTD.htm?0/38/615/abstract/5\">",
"       5",
"      </a>",
"      ]. The positive predictive value was 76 percent for prolonged bleeding from the needle puncture site, 58 percent for difficulty in cannulation, and only 30 percent for aspiration of clots.",
"     </li>",
"     <li>",
"      An unexplained decrease in the delivered dialysis dose",
"      <span class=\"nowrap\">",
"       (Kt/V)",
"      </span>",
"      on a constant hemodialysis prescription. In one prospective study, an unexplained (&gt;0.2 units) decrease in",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      had a 69 percent positive predictive value for significant graft stenosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/615/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, the positive predictive value for angiographically confirmed stenosis is approximately 80, 69 and 66 percent for abnormalities in physical examination of the graft, unexplained decrease in the",
"    <span class=\"nowrap\">",
"     Kt/V,",
"    </span>",
"    and abnormalities in the dialysis session, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/615/abstract/5\">",
"     5",
"    </a>",
"    ]. The major advantages of clinical monitoring are that: it is free; it does not require additional equipment or personnel; and it can be performed by multiple staff members.",
"   </p>",
"   <p>",
"    For these reasons as well as the reported clinical observations (as described in the next section) that none of the surveillance methods improves graft outcomes, we only use clinical monitoring at our institution.",
"   </p>",
"   <p>",
"    However, the proficiency and motivation of dialysis staff to perform such clinical monitoring may vary. If used, this approach can then lead to suboptimal detection of graft stenosis. This was shown in several randomized prospective studies that found that the use of clinical monitoring alone was associated with a rate of angioplasty ranging from 0 to 0.64 events per patient-year [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/615/abstract/5,8,9\">",
"     5,8,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;To overcome the limitations of clinical monitoring, a number of surveillance methods for stenosis have been developed. Unlike clinical monitoring, each of these surveillance methods requires specialized equipment or specially trained staff. The advantage of access surveillance is that it is therefore likely to be performed more consistently and reproducibly than clinical monitoring. However, implementing an access surveillance program requires additional cost, which is not currently reimbursable in the United States. Thus, to justify this added expense, these approaches must demonstrate that their use is associated with improved graft patency.",
"   </p>",
"   <p>",
"    All graft surveillance methods rely upon the observation that progressive graft stenosis results in an increase in intragraft pressure (normalized for systemic blood pressure)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a decrease in access blood flow.",
"   </p>",
"   <p>",
"    The three major types of access surveillance are [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/615/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intra-access blood flow monitoring",
"     </li>",
"     <li>",
"      Static dialysis venous pressure",
"     </li>",
"     <li>",
"      Duplex ultrasound",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Flow monitoring is generally favored over static dialysis venous pressure, although flow monitoring is not as accurate as duplex ultrasound. The main advantage of flow monitoring is that the technique can be done at the bedside in the HD unit, whereas duplex ultrasound requires the patient to go to a hospital or outpatient clinic.",
"   </p>",
"   <p>",
"    Among the different access surveillance methods, we therefore prefer flow monitoring. However, none of the surveillance methods improves graft outcomes, despite a higher frequency of angioplasty. For this reason, we only use clinical monitoring at our institution.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Intra-access blood flow monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intra-access blood flow can be measured by different methods, including Duplex ultrasound, magnetic resonance angiography, dilution based upon ultrasound, urea, or thermal techniques, glucose pump infusion technique, and differential conductivity. The published literature suggests that all the methods of flow monitoring yield largely similar values. Access blood flow measurements are typically performed monthly.",
"   </p>",
"   <p>",
"    Of the available methods, the most commonly utilized flow monitoring technique is ultrasound dilution, which quantifies access blood flow by injecting ice-cold saline via the dialysis needle after reversing the dialysis lines [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/615/abstract/10\">",
"     10",
"    </a>",
"    ]. A sensor measures the rate of increase in temperature following the injection, and uses this information to calculate the access flow rate.",
"   </p>",
"   <p>",
"    Access flows less than 600",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    or a greater than 25 percent decrease in access flow from the baseline value, are suspicious for the presence of hemodynamically significant stenosis. Two prospective studies found that patients with such abnormal access blood flows had an 87 to 100 percent positive predictive value for significant stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/615/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If flow monitoring is used, a fistulogram should be obtained if the flow is &lt;600",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    or &gt;25 percent lower from baseline. However, given the variability of flow measurements, low values should be confirmed before sending a patient for a fistulogram.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Duplex ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Duplex ultrasonography is probably the most reproducible and accurate surveillance method. However, its use is difficult because it is not available at the bedside, and must be done at the clinic or hospital.",
"   </p>",
"   <p>",
"    Duplex ultrasonography measures the peak systolic velocity (PSV) on either side of an area of visual stenosis. The ratio of PSVs measured across the stenotic lesion is calculated. A PSV ratio greater than two is suspicious for significant stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/615/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. In addition, duplex ultrasound can be used to estimate the access blood flow as corroborating evidence for the PSV ratio. In one prospective study, a PSV ratio greater than two was associated with a significant stenosis in 80 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/615/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Static venous dialysis pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;With static venous dialysis pressure, the intra-graft pressure is measured by a manometer hooked up to the dialysis needle, prior to turning on the dialysis pump, and is normalized to the systemic systolic blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/615/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. A ratio of intra-graft to systemic pressure less than 0.4 is considered normal, whereas a ratio greater than 0.6 is suspicious for significant stenosis. Values between 0.4 and 0.6 require repeated measurements for trend analysis. A large prospective study found that abnormal static dialysis venous pressures had a 92 percent positive predictive value for significant stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/615/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Of the available techniques, static venous dialysis pressure is the least utilized in the United States. This is possibly because it is highly operator dependent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     K/DOQI recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;For surveillance of grafts, the 2006",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines prefer the following techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/615/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intra-access flow, using sequential measurements with analysis of trends. These measurements should be performed more frequently than monthly, although the optimal frequency is unclear.",
"     </li>",
"     <li>",
"      Static venous dialysis pressure, either measured or derived. Direct and indirect measurements should be made every two weeks and every week, respectively.",
"     </li>",
"     <li>",
"      Duplex ultrasonography",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With grafts, the",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    work group suggests that surveillance for physical findings suggestive of stenosis, such as persistent arm swelling and other findings, is also acceptable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     When to refer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2006 KDOQI guidelines recommend that clinicians should use the following criteria for additional diagnostic testing and possible treatment in patients with grafts [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/615/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With all techniques, findings with prospective trend analysis consistent with stenosis, rather than a single isolated value",
"     </li>",
"     <li>",
"      Persistent abnormalities with any of the monitoring or surveillance techniques",
"     </li>",
"     <li>",
"      Graft flow rate of less than 600",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      or a greater than 25 percent reduction of access flow from the baseline value.",
"     </li>",
"     <li>",
"      Graft static venous pressure ratio greater than 0.5",
"     </li>",
"     <li>",
"      In grafts, an arterial segment static pressure ratio greater than 0.75",
"     </li>",
"     <li>",
"      A peak systolic velocity (PSV) ratio of greater than two across a stenotic lesion, as measured by duplex ultrasound.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DOES DETECTION OF STENOSIS PREDICT GRAFT THROMBOSIS?",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted previously, noninvasive monitoring methods have a relatively high positive predictive value for detecting greater than 50 percent graft stenosis. However, the ability to detect such a stenotic lesion does not necessarily mean that clinical outcomes are improved, particularly a decreased rate of thrombosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    improved graft survival [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/615/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Abnormalities in clinical monitoring or surveillance have a much lower positive predictive value for thrombosis than for stenosis. In general, fewer than half of grafts with greater than 50 percent stenosis are destined to thrombose without preemptive angioplasty.",
"   </p>",
"   <p>",
"    Unfortunately, there is no reliable test to distinguish between stenosed grafts that will clot and those that will not. Thus, any type of program for prospective stenosis surveillance and preemptive angioplasty necessarily results in a substantial number of superfluous angioplasties. To make matters worse, the vascular injury resulting from angioplasty may actually stimulate neointimal hyperplasia and thereby accelerate graft re-stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/615/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, performance of unnecessary angioplasties in a subset of patients may be justified if it produces an overall reduction in the frequency of graft thrombosis in a large hemodialysis population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     EFFECTIVENESS OF GRAFT MONITORING OR SURVEILLANCE IN REDUCING GRAFT THROMBOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned previously, the vast majority of thrombosed grafts have an underlying stenosis. This observation raises the possibility that detection of significant stenosis in a timely fashion and treatment with preemptive angioplasty may substantially reduce the frequency of graft thrombosis. Since thrombosis is the major cause of graft failure, such an approach may also improve graft longevity.",
"   </p>",
"   <p>",
"    Several observational studies have noted an approximately 40 to 80 percent reduction in graft thrombosis after introducing monitoring or surveillance. The reduction in graft thrombosis was obtained with a variety of methods, including clinical monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/615/abstract/3,6,7,13\">",
"     3,6,7,13",
"    </a>",
"    ], static dialysis venous pressures [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/615/abstract/13\">",
"     13",
"    </a>",
"    ], or duplex ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/615/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There have been six randomized clinical trials comparing the impact of graft surveillance to clinical monitoring on graft outcomes. The surveillance method was duplex ultrasound in four studies, access flow in two studies, and static dialysis venous pressure in one study (one study included two different surveillance methods) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/615/abstract/5,8,11,18-20\">",
"     5,8,11,18-20",
"    </a>",
"    ]. In contrast to the observational studies, five out of five randomized controlled trials have shown no benefit of graft surveillance in reducing graft thrombosis, and only one out of five observed an increase in graft longevity [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/615/abstract/5,8,11,18-20\">",
"     5,8,11,18-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 2008 meta-analysis of randomized studies that evaluated graft found no decrease in the risk of thrombosis (relative risk of 0.94; 95% CI, 0.77 to 1.16; 446 participants) or access loss (RR of 1.08; 95% CI, 0.83 to 1.40) with monitoring or surveillance compared with historic controls without the use of such techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/615/abstract/21\">",
"     21",
"    </a>",
"    ]. Thus, at best, graft surveillance with preemptive angioplasty may decrease graft thrombosis by up to 23 percent, a much more modest benefit than that obtained in the observational studies. However, it may also increase graft thrombosis by 16 percent.",
"   </p>",
"   <p>",
"    Thus, current published evidence suggests that surveillance with preemptive angioplasty for stenosis does NOT decrease the frequency of graft thrombosis or improve survival. Possible reasons for this observation include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Benefits may be limited to relatively new grafts. This is supported by an observational study in which the benefit of graft surveillance and preemptive angioplasty was greatest in grafts less than three months of age [",
"      <a class=\"abstract\" href=\"UTD.htm?0/38/615/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Thrombosis-free graft survival may be most likely observed in grafts without a previous intervention [",
"      <a class=\"abstract\" href=\"UTD.htm?0/38/615/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There may be an insufficient opportunity to noninvasively detect the stenosis due to the rapid progression of the lesion in grafts with early thrombosis. This is supported by the 20 to 25 percent false negative rate observed with graft surveillance [",
"      <a class=\"abstract\" href=\"UTD.htm?0/38/615/abstract/9,24\">",
"       9,24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Benefits may be very short lived, due perhaps to restenosis after angioplasty [",
"      <a class=\"abstract\" href=\"UTD.htm?0/38/615/abstract/12,16,25\">",
"       12,16,25",
"      </a>",
"      ]. In this regard, it has been proposed that covered stents (graft-stents) may prolong graft patency following balloon angioplasty by delaying re-stenosis due to neointimal hyperplasia. To evaluate this hypothesis, a multi-center clinical trial assigned 190 patients with greater than 50 percent stenosis at the graft-vein anastomosis to treatment with a graft-stent or with conventional balloon angioplasty [",
"      <a class=\"abstract\" href=\"UTD.htm?0/38/615/abstract/26\">",
"       26",
"      </a>",
"      ]. Patients underwent protocol angiograms two and six months after the initial intervention. At six months, patients treated with a graft-stent had a higher treatment area patency (51 versus 23 percent) and a higher overall graft patency (38 versus 20 percent). However, there was no difference in the likelihood of graft thrombosis (33 versus 21 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/38/615/abstract/26\">",
"       26",
"      </a>",
"      ]. In other words, graft-stents reduced the re-stenosis rate but did not prevent graft thrombosis. Given this discrepancy, it is uncertain whether the added cost of graft-stents is justified in the routine treatment of graft stenosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     OUR APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Current published evidence suggests that surveillance with preemptive angioplasty for stenosis does NOT decrease the frequency of graft thrombosis or improve survival. Thus, we currently do not use any type of graft surveillance.",
"   </p>",
"   <p>",
"    Instead, the dialysis staff performs physical examination of the graft weekly, and notes any abnormalities during the dialysis session. Abnormalities on physical examination or problems with dialysis prompt a fistulogram. Similarly, an unexplained (&gt;0.2 units) persistent decrease in",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    prompts a fistulogram.",
"   </p>",
"   <p>",
"    If a hemodialysis unit is not able or willing to do clinical monitoring, the next best option is flow monitoring. The threshold for referral for a graft is a flow &lt;600",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    or &gt;25 percent decrease from baseline. These abnormal values should be confirmed before proceeding to a fistulogram.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/22/11619?source=see_link\">",
"       \"Patient information: Preparing for hemodialysis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Greater than 90 percent of thrombosed grafts have a stenotic lesion, suggesting that such an anatomic abnormality is required for graft thrombosis. Noninvasive assessment is preferred for efficient screening to identify those grafts most likely to be stenotic. Currently, assessment of hemodialysis AV grafts for stenosis is performed by both clinical monitoring and noninvasive surveillance. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prospective monitoring and surveillance for stenosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical monitoring falls into the following three broad categories: abnormalities of physical examination; problems noted during the dialysis session; and an unexplained decrease in the delivered dialysis dose",
"      <span class=\"nowrap\">",
"       (Kt/V)",
"      </span>",
"      on a constant hemodialysis prescription. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The three major types of access surveillance are intra-access blood flow monitoring, static dialysis venous pressure, and duplex ultrasound. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Surveillance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Current published evidence suggests that surveillance with preemptive angioplasty for stenosis does NOT decrease the frequency of graft thrombosis or improve survival. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Effectiveness of graft monitoring or surveillance in reducing graft thrombosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      At our center, the dialysis staff performs physical examination of the graft weekly. Abnormalities on physical examination or problems with dialysis prompt a fistulogram. Similarly, an unexplained (&gt;0.2 units) persistent decrease in",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      prompts a fistulogram. If a hemodialysis unit is not able or willing to do clinical monitoring, the next best option is flow monitoring. The threshold for referral for a graft is a flow &lt;600",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      or &gt;25 percent decrease from baseline. These abnormal values should be confirmed before proceeding to a fistulogram. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Our approach'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/615/abstract/1\">",
"      Allon M, Robbin ML. Hemodialysis vascular access monitoring: current concepts. Hemodial Int 2009; 13:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/615/abstract/2\">",
"      Maya ID, Oser R, Saddekni S, et al. Vascular access stenosis: comparison of arteriovenous grafts and fistulas. Am J Kidney Dis 2004; 44:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/615/abstract/3\">",
"      Cayco AV, Abu-Alfa AK, Mahnensmith RL, Perazella MA. Reduction in arteriovenous graft impairment: results of a vascular access surveillance protocol. Am J Kidney Dis 1998; 32:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/615/abstract/4\">",
"      Robbin ML, Oser RF, Allon M, et al. Hemodialysis access graft stenosis: US detection. Radiology 1998; 208:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/615/abstract/5\">",
"      Robbin ML, Oser RF, Lee JY, et al. Randomized comparison of ultrasound surveillance and clinical monitoring on arteriovenous graft outcomes. Kidney Int 2006; 69:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/615/abstract/6\">",
"      Safa AA, Valji K, Roberts AC, et al. Detection and treatment of dysfunctional hemodialysis access grafts: effect of a surveillance program on graft patency and the incidence of thrombosis. Radiology 1996; 199:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/615/abstract/7\">",
"      Schwab SJ, Raymond JR, Saeed M, et al. Prevention of hemodialysis fistula thrombosis. Early detection of venous stenoses. Kidney Int 1989; 36:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/615/abstract/8\">",
"      Lumsden AB, MacDonald MJ, Kikeri D, et al. Prophylactic balloon angioplasty fails to prolong the patency of expanded polytetrafluoroethylene arteriovenous grafts: results of a prospective randomized study. J Vasc Surg 1997; 26:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/615/abstract/9\">",
"      Dember LM, Holmberg EF, Kaufman JS. Value of static venous pressure for predicting arteriovenous graft thrombosis. Kidney Int 2002; 61:1899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/615/abstract/10\">",
"      Krivitski NM. Theory and validation of access flow measurement by dilution technique during hemodialysis. Kidney Int 1995; 48:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/615/abstract/11\">",
"      Moist LM, Churchill DN, House AA, et al. Regular monitoring of access flow compared with monitoring of venous pressure fails to improve graft survival. J Am Soc Nephrol 2003; 14:2645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/615/abstract/12\">",
"      Schwab SJ, Oliver MJ, Suhocki P, McCann R. Hemodialysis arteriovenous access: detection of stenosis and response to treatment by vascular access blood flow. Kidney Int 2001; 59:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/615/abstract/13\">",
"      Besarab A, Sullivan KL, Ross RP, Moritz MJ. Utility of intra-access pressure monitoring in detecting and correcting venous outlet stenoses prior to thrombosis. Kidney Int 1995; 47:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/615/abstract/14\">",
"      Besarab A, Frinak S, Sherman RA, et al. Simplified measurement of intra-access pressure. J Am Soc Nephrol 1998; 9:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/615/abstract/15\">",
"      KDOQI clinical practice guidelines and clinical practice recommendations for vascular access 2006. Am J Kidney Dis 2006; 48 (suppl 1): S176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/615/abstract/16\">",
"      Chang CJ, Ko PJ, Hsu LA, et al. Highly increased cell proliferation activity in the restenotic hemodialysis vascular access after percutaneous transluminal angioplasty: implication in prevention of restenosis. Am J Kidney Dis 2004; 43:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/615/abstract/17\">",
"      McCarley P, Wingard RL, Shyr Y, et al. Vascular access blood flow monitoring reduces access morbidity and costs. Kidney Int 2001; 60:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/615/abstract/18\">",
"      Ram SJ, Work J, Caldito GC, et al. A randomized controlled trial of blood flow and stenosis surveillance of hemodialysis grafts. Kidney Int 2003; 64:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/615/abstract/19\">",
"      Dember LM, Holmberg EF, Kaufman JS. Randomized controlled trial of prophylactic repair of hemodialysis arteriovenous graft stenosis. Kidney Int 2004; 66:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/615/abstract/20\">",
"      Malik J, Slavikova M, Svobodova J, Tuka V. Regular ultrasonographic screening significantly prolongs patency of PTFE grafts. Kidney Int 2005; 67:1554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/615/abstract/21\">",
"      Tonelli M, James M, Wiebe N, et al. Ultrasound monitoring to detect access stenosis in hemodialysis patients: a systematic review. Am J Kidney Dis 2008; 51:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/615/abstract/22\">",
"      Miller CD, Robbin ML, Barker J, Allon M. Comparison of arteriovenous grafts in the thigh and upper extremities in hemodialysis patients. J Am Soc Nephrol 2003; 14:2942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/615/abstract/23\">",
"      Martin LG, MacDonald MJ, Kikeri D, et al. Prophylactic angioplasty reduces thrombosis in virgin ePTFE arteriovenous dialysis grafts with greater than 50% stenosis: subset analysis of a prospectively randomized study. J Vasc Interv Radiol 1999; 10:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/615/abstract/24\">",
"      McDougal G, Agarwal R. Clinical performance characteristics of hemodialysis graft monitoring. Kidney Int 2001; 60:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/615/abstract/25\">",
"      Murray BM, Rajczak S, Ali B, et al. Assessment of access blood flow after preemptive angioplasty. Am J Kidney Dis 2001; 37:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/615/abstract/26\">",
"      Haskal ZJ, Trerotola S, Dolmatch B, et al. Stent graft versus balloon angioplasty for failing dialysis-access grafts. N Engl J Med 2010; 362:494.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1965 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.211.0.116-06C3FA9DAE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_38_615=[""].join("\n");
var outline_f0_38_615=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROSPECTIVE MONITORING AND SURVEILLANCE FOR STENOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Clinical monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Surveillance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Intra-access blood flow monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Duplex ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Static venous dialysis pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      K/DOQI recommendations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - When to refer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DOES DETECTION OF STENOSIS PREDICT GRAFT THROMBOSIS?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      EFFECTIVENESS OF GRAFT MONITORING OR SURVEILLANCE IN REDUCING GRAFT THROMBOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      OUR APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/16/23816?source=related_link\">",
"      Arteriovenous fistulas and grafts for chronic hemodialysis access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/50/27429?source=related_link\">",
"      Monitoring and surveillance of hemodialysis arteriovenous fistulas to prevent thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/22/11619?source=related_link\">",
"      Patient information: Preparing for hemodialysis (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_38_616="Unstable hemoglobin variants";
var content_f0_38_616=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Unstable hemoglobin variants",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/38/616/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/38/616/contributors\">",
"     Martin H Steinberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/38/616/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/38/616/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/38/616/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/38/616/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/38/616/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some mutations of hemoglobin (Hb) decrease the solubility of the molecule in the red cell. Substitutions in the primary sequence of globin in these unstable hemoglobins can alter the tertiary or quaternary structure of the molecule and result in a globin",
"    <span class=\"nowrap\">",
"     polypeptide/hemoglobin",
"    </span>",
"    tetramer that is unstable and precipitates intracellularly. These intraerythrocytic precipitates are detectable with the aid of supravital staining as dark globular aggregates called Heinz bodies (",
"    <a class=\"graphic graphic_picture graphicRef73790 \" href=\"UTD.htm?25/28/26054\">",
"     picture 1",
"    </a>",
"    ). The affected red cells have a reduced life span producing a hemolytic syndrome of varied severity called the congenital Heinz body hemolytic anemia syndrome. This disorder can also be caused by some inherited erythrocyte enzyme deficiencies.",
"   </p>",
"   <p>",
"    As of January 2010, approximately 140 of 1028 known mutations of hemoglobin are found to be unstable; abnormalities the alpha-, beta-, gamma- and delta-globin chains have been described. Of these infrequent mutations, Hb K&ouml;ln is the most commonly reported. The clinical presentation is of a slight to moderate, usually normocytic anemia that may be accompanied by splenomegaly. The diagnosis is established by the detection of Heinz bodies in red cells, the demonstration of hemoglobin instability in the red cell hemolysate, and the presence of pigmenturia. Supportive measures and, in occasional patients, splenectomy, are the available treatment modalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS OF UNSTABLE HEMOGLOBINS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unstable hemoglobins are uncommon mutational events, generally limited to a single pedigree [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/616/abstract/1\">",
"     1",
"    </a>",
"    ]. However, Hb K&ouml;ln (HBB val98met) has been detected in several different pedigrees and geographical locations [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/616/abstract/2\">",
"     2",
"    </a>",
"    ] and Hb Hasharon (HBA2 asp47his), is found predominantly among Ashkenazi Jews, causing hemolysis in newborns [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/616/abstract/3\">",
"     3",
"    </a>",
"    ]. Unstable gamma chain variants, such as Hb Poole (HBG trp130gly) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/616/abstract/4\">",
"     4",
"    </a>",
"    ], are associated with hemolysis in the first few months of life, which disappear as gamma-globin chain synthesis decreases during the first year. On the other hand, children with unstable beta-globin chain variants may appear normal at birth, with progressive hemolysis appearing during the first year of life as beta- globin chain production increases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with unstable hemoglobins can present in a number of ways:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Congenital nonspherocytic hemolytic anemia with splenomegaly and pigmented (bilirubin) gallstones",
"     </li>",
"     <li>",
"      Heinz body hemolytic anemia with sensitivity to oxidant drugs, such as sulfonamides",
"     </li>",
"     <li>",
"      Mild or minimal anemia with reticulocytosis out of proportion to the level of circulating hemoglobin",
"     </li>",
"     <li>",
"      A thalassemia-like peripheral blood picture with hypochromic red blood cells",
"     </li>",
"     <li>",
"      Increased formation of methemoglobin",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Hemolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemolytic anemia, the chief clinical feature of unstable hemoglobins, varies considerably in its intensity depending upon the nature of the mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/616/abstract/5\">",
"     5",
"    </a>",
"    ]. There are also variations within pedigrees. Among adult carriers with Hb Hasharon, for example, the manifestations vary from mild anemia, to no hemolysis. Epistatic effects of other nonlinked modifier genes may be responsible for these differences.",
"   </p>",
"   <p>",
"    Patients with unstable hemoglobins can have hemolytic crises, characterized by an abrupt increase in hemolysis beyond the steady state levels. This complication may follow bacterial or viral infections or exposure to chemical oxidants.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mechanism of infection-mediated hemolysis is not clear, but pyrexia and transient acidosis may contribute since both can increase hemoglobin denaturation.",
"     </li>",
"     <li>",
"      As in all patients with chronic hemolysis, parvovirus B19 can induce an aplastic crisis with severe anemia in carriers of unstable hemoglobins. This acute, transitory and generally self-limited aplastic event is due to viral invasion of BFU-E in the marrow using the P (blood group) antigen as receptor. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/54/22377?source=see_link\">",
"       \"Clinical manifestations and pathogenesis of human parvovirus B19 infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chronic intravascular hemolysis can be associated with pulmonary hypertension [",
"      <a class=\"abstract\" href=\"UTD.htm?0/38/616/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Drugs with oxidant potential, such as sulfonamides, have been directly implicated in hemolytic crises associated with Hb Zurich, Hb Hasharon, Hb Shepards Bush, and Hb Peterborough. These crises are generally self-limited and it is prudent to discontinue possible offending drugs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pigmenturia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with unstable hemoglobins may have dark urine (pigmenturia) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/616/abstract/5\">",
"     5",
"    </a>",
"    ]. This color change is due to the presence of dipyrrole methenes of the mesobilifuscin group. The origin of these fluorescent compounds is not clear. Their structure, two pyrrole rings still bound to each other by a methenyl bridge, suggests the malfunctioning of methenyl oxygenase, the enzyme involved in the breaking of -CH= bridges. Fluorescent dipyrroles are also present in Heinz bodies [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/616/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The absence of pigmenturia does not exclude the diagnosis of unstable hemoglobin, since not all of these mutants exhibit pigmenturia and the severity of the hemolysis is unrelated to pigmenturia. As an example, pigmenturia can be seen in carriers of both Hb K&ouml;ln and Hb Zurich, but hemolysis may be severe with Hb K&ouml;ln and very mild in Hb Zurich.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY OF UNSTABLE HEMOGLOBINS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of mechanisms contribute to the instability of these mutant hemoglobins. These include mutations that weaken or modify the heme-globin interactions, that interfere with the secondary or tertiary structure of the subunits, or that interfere with subunit interactions. The structure and function of normal hemoglobin are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/29/23001?source=see_link\">",
"     \"Structure and function of normal human hemoglobins\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Mutations that weaken or modify the heme-globin interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heme binding to globin is important for the oxygen binding properties and the stability and solubility of the molecule. Several of the mutations involving residues with defined interactions with the heme groups that result in an unstable hemoglobin are depicted in the figure (",
"    <a class=\"graphic graphic_figure graphicRef58767 \" href=\"UTD.htm?10/43/10933\">",
"     figure 1",
"    </a>",
"    ). These include substitutions that introduce into the heme pocket a charged side chain where a nonpolar side chain existed previously, deletions involving residues that directly interact with heme, and nontyrosine substitutions of the proximal histidine. Observations in patients with Hb Zurich and Hb K&ouml;ln illustrate these mechanisms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Hb Zurich",
"    </span>",
"    &nbsp;&mdash;&nbsp;In Hb Zurich (HBB his63arg), substitution of the distal histidine in the beta-globin chains enlarges the space available for ligand binding around the iron, fundamentally modifying its ligand properties [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/616/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. This steric change has little effect on the angled binding of oxygen to iron but it makes a significant difference for carbon monoxide (CO) that binds perpendicular to the heme. The steric constraints of the normal heme pocket reduce CO binding to iron compared with oxygen; this represents an important adaptation to the endogenous generation of CO (one CO molecule evolves from each molecule of heme catabolized) since it protects hemoglobin from being bound to CO in excess. CO toxicity stems from a significant reduction in the dissociation constant of its binding to hemoglobin, compared with oxygen, making carboxyhemoglobin (COHb) a particularly stable compound.",
"   </p>",
"   <p>",
"    Carriers of Hb Zurich have an enhanced affinity for CO (approximately 65-fold) due to an increase in the binding constant [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/616/abstract/10\">",
"     10",
"    </a>",
"    ]. This molecular pathology is, in effect, a protective mechanism since it does not allow the abnormal beta-globin chain heme group to be oxidized to the ferric form, which would increase its instability. COHb levels are very high in smokers with Hb Zurich due to the CO content of tobacco smoke, but are also elevated in nonsmoking carriers due to endogenous CO production. Due to the partially protective effect of COHb Zurich, the rate of hemolysis is reduced and Heinz bodies are less frequent among smokers than nonsmokers with this abnormal hemoglobin [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/616/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hb Zurich carriers have a special susceptibility to hemolytic crisis induced by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/17/39186?source=see_link\">",
"     sulfanilamide",
"    </a>",
"    . Because of the increased size of the heme pocket, sulfanilamide binds to heme directly and produces methemoglobin. Because CO inhibits this reaction, smoking protects these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Hb K&ouml;ln",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hb K&ouml;ln, the most frequently diagnosed unstable hemoglobin in the West, is characterized by mild anemia, reticulocytosis, splenomegaly, and pigmenturia; it is expressed at a 10 to 25 percent level [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/616/abstract/2\">",
"     2",
"    </a>",
"    ]. This mutation involves a residue in the heme pocket that is very close to the F8His, the proximal histidine that is involved in a valency bond with heme iron.",
"   </p>",
"   <p>",
"    The functional properties of Hb K&ouml;ln involve a high oxygen affinity in the absence of compensatory erythrocytosis and easy heme dissociation. Of special interest are the abnormalities in the membrane of erythrocytes containing Hb K&ouml;ln. When the patient's red cells are exposed to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    stress, they produce twice the malonylaldehyde (a lipid peroxidation product) than normal red cells. Two sorts of abnormal membrane aggregates have been found in those patients with Hb K&ouml;ln who have undergone splenectomy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A disulfide bond between membrane band 3 (AE-1 or the anion exchanger) and globin",
"     </li>",
"     <li>",
"      Aggregates of spectrin and other membrane components, which have an amino acid composition similar to normal membranes exposed to malonylaldehyde.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These membrane-associated aggregates are thought to reduce the deformability of Hb K&ouml;ln erythrocytes, thereby contributing to the hemolysis. In addition, denatured hemoglobin coclusters with the red cell membrane band 3, resulting in increased binding of autoantibodies against this band 3 [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/616/abstract/11\">",
"     11",
"    </a>",
"    ]. This process may be important physiologically in aged red cells when hemoglobin begins to denature; it promotes recognition by macrophages and contributes to the removal of senescent cells.",
"   </p>",
"   <p>",
"    Red cells containing Hb K&ouml;ln have a green fluorescent pigment due to dipyrroles, the same pigment found in the pigmented urine of these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/616/abstract/7\">",
"     7",
"    </a>",
"    ]. The partial lack of hemes in some of the tetramers of Hb K&ouml;ln makes the use of pulse oximetry unreliable in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Mutations that interfere with the secondary structure of the subunits",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 75 percent of hemoglobin is in the form of an alpha-helix, and any disruption of this secondary structure reduces the solubility of the subunit. Unstable hemoglobin mutants can result from the introduction of proline in the helical structure or the substitution of glycine by a mutation in invariant positions in the interhelical bends.",
"   </p>",
"   <p>",
"    About 30 unstable hemoglobins with single or double substitutions involve the introduction of a proline residue. An example is Hb Brockton (HBB ala138pro), an abnormality that is associated with mild anemia. Crystallographic examination showed that the tertiary structure was disrupted in the vicinity of the mutated residue [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/616/abstract/12\">",
"     12",
"    </a>",
"    ]. Molecular instability was probably due to breakage of a buried hydrogen bond. Hb Brockton cannot be separated from Hb A with standard electrophoretic procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/616/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Mutations that interfere with the tertiary structure of the subunit",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemoglobin is a tight globular protein; as a result, alpha-helical regions must be folded into a solid sphere. This design introduces enormous constraints to its architecture. Substitutions in the sequence of residues that point inward can occur with no change in solubility as long as the incoming residue is not charged, is not bulky, or there is no loss of critical nonpolar residues that prevent water from entering the interior of the molecule. Approximately one-half of unstable hemoglobins that interfere with this tertiary structure result from the substitution of arginine for leucine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Mutations that affect subunit interactions: interference with the quaternary structure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Introduction of charged residues in the interior or the loss of intersubunit contact hydrogen bonds or salt bridges in the alpha1 beta1 contact area produces hemoglobin instability. This area of contact is normally very strong and difficult to dissociate. When a substitution weakens the contact area, it promotes the breakdown of alpha1beta1 dimers into monomers, generating methemoglobin with consequent instability. Dissociation of chains along the alpha1beta1 contact generates alpha and beta-globin chains that uncoil, loosening their heme-globin interaction, and favoring methemoglobin formation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Hyperunstable hemoglobins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperunstable hemoglobins are either barely detectable or undetectable in the hemolysate. These rare hemoglobins are presumably synthesized normally but are rapidly destroyed because of extreme instability, creating the phenotype of dominant inherited thalassemia. The latter syndrome refers to a heterozygous individual who has a phenotype of severe thalassemia, normally associated with compound heterozygosity or homozygosity for thalassemia mutations.",
"   </p>",
"   <p>",
"    One of the first examples of this phenotype was Hb Indianapolis (HBB leu106arg, previously identified as cys112arg) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/616/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Hb Indianapolis was not detectable in the hemolysate but its beta-globin chain could be detected by biosynthetic means and had a calculated half-life of less than 10 minutes. The proband and his daughter were transfusion dependent with all the features of severe beta-thalassemia. Unlike the typical severe thalassemia, the phenotype was inherited in a dominant manner. Erythrocyte membrane damage by the labile beta-globin chain and unpaired alpha-globin chains were felt to account for the severe phenotype.",
"   </p>",
"   <p>",
"    Another example is Hb Petah Tikva (HBA ala110asp), a special case among unstable hemoglobins. Found in two unrelated Iraqi Jewish children, the phenotype appeared to be an alpha-thalassemia with hematologic characteristics of mild Hb H disease, suggesting that the children had inherited only a single alpha-chain gene instead of the usual four [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/616/abstract/15\">",
"     15",
"    </a>",
"    ]. The mutated hemoglobin could not be separated by electrophoresis, but the abnormal alpha-chain was detected by HPLC. The hemolysate was unstable, and the precipitated material was enriched in the mutant globin chain. Each child had one parent with alpha-thalassemia trait and the other was heterozygous for Hb Petah Tikva. Each affected patient appeared to be compound heterozygotes for both alpha-thalassemia trait and Hb Petah Tikva.",
"   </p>",
"   <p>",
"    Synthesis studies in heterozygotes for Hb Petah Tikva (PT) revealed that only traces of alpha PT were synthesized by reticulocytes. In the compound heterozygous patients, both mutated and normal alpha-chains were synthesized by bone marrow erythroid precursors at rates related to their concentration in blood. In contrast, there was a considerable decrease in alpha PT synthesis in reticulocytes. Thus, the phenotype of these patients was the consequence of the triad of alpha-thalassemia, the unstable alpha PT variant, and its premature termination of synthesis during erythroid differentiation.",
"   </p>",
"   <p>",
"    Hb Bristol-Alesha, another hyperunstable Hb, is caused by a GTG to ATG mutation at codon 67 in the HBB, resulting in a change from val67met or val67asp [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/616/abstract/16\">",
"     16",
"    </a>",
"    ]. This abnormal hemoglobin was described in a Japanese child diagnosed with hemolytic anemia at six months of age. The development of marked splenomegaly necessitated RBC transfusions",
"    <span class=\"nowrap\">",
"     twice/month;",
"    </span>",
"    splenectomy at four years of age enhanced the hemolytic anemia.",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     alpha/beta",
"    </span>",
"    globin synthesis ratio in this child's hemoglobin was abnormal at 2.22. After splenectomy, there was the presence of abnormal beta-globin chains with a beta67val: beta67met: beta67asp molecule ratio of 74:11:15. It was speculated that the high fraction of the beta67met molecule caused the extreme Hb instability, resulting in a thalassemic hyperunstable hemoglobinopathy and very severe clinical findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Heinz body formation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heinz bodies, which are intraerythrocytic precipitates, are the product of hemoglobin denaturation and the production of hemichromes. The latter are generated when the heme is dissociated from the heme pocket and rebinds elsewhere in the globin after the alpha- or the beta-chains have suffered some uncoiling or denaturation. Irreversible hemichromes seem to be an indispensable stage in the formation of Heinz bodies (",
"    <a class=\"graphic graphic_picture graphicRef73790 \" href=\"UTD.htm?25/28/26054\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/616/abstract/17\">",
"     17",
"    </a>",
"    ], which contain both alpha- and beta-globin chains [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/616/abstract/18\">",
"     18",
"    </a>",
"    ]. As a general rule, weakening of the heme-globin bond will accelerate hemoglobin denaturation.",
"   </p>",
"   <p>",
"    Heinz bodies, at least partially, adhere to the cytosolic face of the erythrocyte membrane by hydrophobic interactions [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/616/abstract/19\">",
"     19",
"    </a>",
"    ]. Band 3, one of the most abundant erythrocyte transmembrane proteins, has a highly glycosylated portion on the red cell surface, a hydrophobic portion spanning the lipid bilayer, and an N-terminal cytosolic domain that has two conformational independent portions separated by a protease sensitive hinge region. The N-terminal domain is highly negatively charged, and has a high content of proline and other amino acid residues that do not accommodate well in an alpha-helix. Hemoglobin and hemichromes bind the most N-terminal portion of the cytosolic domain [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/616/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Band 3 cytosolic sequences can thread into the positively charged central cavity of hemoglobin, which is why it preferentially and reversibly binds deoxyhemoglobin [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/616/abstract/21\">",
"     21",
"    </a>",
"    ]. Hemoglobins with the greatest positive charge have the highest affinity for band 3. Hb A2 and Hb C attach tenaciously to the membrane, while Hb S has an affinity intermediate between Hb A and Hb C. The net result of these interactions is the formation of single or multiple aggregates of membrane proteins and denatured globin which make the red cell poorly deformable (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Mechanisms of anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heinz body-containing erythrocytes have a reduced life span that may be due to a variety of factors. Unstable hemoglobins generate considerable hemichrome that may bind band 3. These erythrocytes have decreased deformability, a characteristic that condemns them to be preferentially trapped in the spleen. It is possible that the inclusions of Heinz body-containing red cells are initially pitted in the spleen. Pitting refers to the mechanism by which a portion of the membrane, with the Heinz body inclusion, is excised from the cell during its passage through the sinusoidal slits in the spleen, with the initial event causing the formation of a \"bite\" or \"blister\" cell (",
"    <a class=\"graphic graphic_picture graphicRef73790 \" href=\"UTD.htm?25/28/26054\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/616/abstract/22\">",
"     22",
"    </a>",
"    ]. This membrane loss progressively converts erythrocytes into spherocytes, which are rigid cells that are eventually removed from the circulation.",
"   </p>",
"   <p>",
"    Other sources of potential membrane damage are a result of peroxidation and protein cross-linking of membrane proteins. These are probably secondary to the presence of free heme iron that acts as a Fenton reagent, decompartmentalization of iron, and the generation of free radicals secondary to methemoglobin formation and hemoglobin denaturation.",
"   </p>",
"   <p>",
"    A further determinant of the anemia is the oxygen equilibrium curve. While red cell 2,3-DPG levels are generally normal, some of the unstable variants have either a high or low oxygen affinity. Unstable variants with high oxygen affinity tend to have milder anemia because of increased red cell formation induced by erythropoietin&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/616/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     INSTABILITY OF COMMON HEMOGLOBINS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Hemoglobin A2",
"    </span>",
"    &nbsp;&mdash;&nbsp;HbA2",
"    <span class=\"nowrap\">",
"     (alpha2/delta2)",
"    </span>",
"    is an important minor normal hemoglobin variant which comprises 2 to 3 percent of hemoglobin in circulating adult RBCs. Its increased concentration in beta-thalassemia is a useful clinical diagnostic tool. In beta-thalassemia major, where there is beta-chain production failure, HbA2 acts as the predominant oxygen deliverer. HbA2 has two additional important features: it is more resistant to thermal denaturation than HbA, and it is capable of inhibiting the polymerization of deoxy sickle hemoglobin (HbS) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/616/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/29/23001?source=see_link&amp;anchor=H18#H18\">",
"     \"Structure and function of normal human hemoglobins\", section on 'Hemoglobin A2'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Hemoglobin E",
"    </span>",
"    &nbsp;&mdash;&nbsp;HbE, formed as a result of a splice site mutation on exon 1 of the beta-globin gene, is an important and frequent hemoglobin variant, particularly in Southeast Asia. It is known to be unstable at high temperatures. Both heterozygous HbAE and homozygous HbEE are benign disorders, but when HbE combines with beta-thalassemia, it usually causes a severe phenotype. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/58/9129?source=see_link&amp;anchor=H23#H23\">",
"     \"Molecular pathology of the thalassemic syndromes\", section on 'Hb E: A special case'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The crystal structures of HbA2 and HbE have been established at 2.20 and 1.74 angstroms resolution, respectively, which have provided probable explanations for the thermal stability and instability of HbA2 and HbE, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/616/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of an unstable hemoglobinopathy in adults includes other causes of congenital nonspherocytic hemolytic anemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    Heinz body hemolytic syndrome, such as the erythrocyte enzymopathies:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pyruvate kinase deficiency",
"     </li>",
"     <li>",
"      Glucose-6-phosphate dehydrogenase deficiency",
"     </li>",
"     <li>",
"      Glutathione reductase deficiency",
"     </li>",
"     <li>",
"      Gamma-glutamyl cysteine synthetase deficiency",
"     </li>",
"     <li>",
"      Glutathione synthetase deficiency",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Acquired forms of Heinz body hemolytic anemia, such as acquired methemoglobinemia due to chemicals and drugs, and, in young adults and children, Wilson's disease and erythropoietic porphyria, have to be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/616/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. In rare cases, several of these entities may interact, making diagnosis difficult. Another potential diagnostic problem is that the spleen may be so efficient in removing Heinz bodies that they cannot be found in the circulation. When Heinz bodies cannot be found, the possibility of autoimmune hemolytic anemia should be raised. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/46/4841?source=see_link\">",
"     \"Genetics and pathogenesis of methemoglobinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of an unstable hemoglobin variant is established by the detection of Heinz bodies in red cells, the demonstration of hemoglobin instability in the red cell hemolysate, and the presence of pigmenturia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Peripheral blood smear and Heinz body preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormalities on the peripheral blood smear are not specific for unstable hemoglobins. Anisocytosis, often prominent basophilic stippling, Howell-Jolly bodies, nucleated red blood cells, and microspherocytes may be found. The red blood cells may be hypochromic with a reduced mean corpuscular hemoglobin due to removal of some of the denatured globin chains as Heinz bodies by the spleen. This may be especially prominent in the hyperunstable hemoglobin variants, leading to a thalassemia-like picture.",
"   </p>",
"   <p>",
"    Heinz body detection requires preincubation of erythrocytes with a supravital stain such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"     methylene blue",
"    </a>",
"    , crystal violet, or brilliant cresyl blue (",
"    <a class=\"graphic graphic_picture graphicRef73790 \" href=\"UTD.htm?25/28/26054\">",
"     picture 1",
"    </a>",
"    ). Heinz bodies appear as single or multiple pale purple inclusions that are 2 microns in diameter or less; they frequently appear to be membrane attached. Heinz bodies may be found in freshly drawn samples of peripheral blood but, in most cases, incubation for 24 hours in the absence of glucose is required for them to form. Due to the extreme variability inherent in this test, a normal blood sample as a control should always be run simultaneously. Heinz bodies become easier to detect after splenectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Hemoglobin studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;About 25 percent of unstable hemoglobins cannot be detected by HPLC or other means of hemoglobin separation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/616/abstract/5\">",
"     5",
"    </a>",
"    ]. In many cases, the unstable hemoglobin appears as a diffuse, rather than a sharply defined band. This alteration is probably secondary to the partial denaturation of hemoglobin molecules during electrophoresis or during pre-electrophoresis processing of the hemolysate. Occasionally, only precipitated material at the origin is observed. DNA-based methodologies will definitively establish the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/60/968?source=see_link\">",
"     \"Laboratory diagnosis of the hemoglobinopathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Stability tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The heat stability or heat denaturation test is a simple procedure in which the hemolysate is incubated for one or two hours at 50&ordm;C [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/616/abstract/27\">",
"     27",
"    </a>",
"    ]. Normal hemolysates are stable under these conditions; the presence of an unstable hemoglobin is signaled by the appearance of a visible precipitate [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/616/abstract/18,28-30\">",
"     18,28-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The isopropanol stability test is also useful, but can be confounded by increased levels of HbF, HbS, and methemoglobin [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/616/abstract/31\">",
"     31",
"    </a>",
"    ]. Mechanical agitation can also precipitate some unstable hemoglobins [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/616/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital Heinz body hemolytic anemias due to unstable hemoglobins are generally mild disorders that do not require therapy, except for supportive and preventive measures, including administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    to insure that an overworked marrow does not become deficient in this nutrient, prevention and prompt treatment of infections, and avoidance of oxidant drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Splenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The question of splenectomy arises in patients with more severe hemolysis. Although the spleen plays an important pathophysiologic role in the destruction of Heinz body-containing red cells, the potential benefit of splenectomy must be weighed against the increased susceptibility to pneumococcal infections early in life, and the need for pneumococcal vaccine and prophylactic penicillin when splenectomy is performed during childhood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/1/20506?source=see_link&amp;anchor=H10#H10\">",
"     \"Hereditary spherocytosis: Clinical features; diagnosis; and treatment\", section on 'Splenectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On balance, splenectomy is often beneficial for the most severe cases of unstable hemoglobinopathies, and partial correction of the anemia has been achieved in some instances [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/616/abstract/5\">",
"     5",
"    </a>",
"    ]. However, for unknown reasons, splenectomy does not always reduce hemolysis or anemia.",
"   </p>",
"   <p>",
"    Thromboembolic events have also been noted following splenectomy for unstable hemoglobin [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/616/abstract/34\">",
"     34",
"    </a>",
"    ]. The etiology of the increased tendency to thrombosis in congenital hemolytic anemia is likely to be multifactorial, but postsplenectomy erythrocytosis, red cell procoagulant-containing microparticles, and post-splenectomy thrombocytosis may play some role.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     Hydroxyurea",
"    </a>",
"    has stimulated HbF production in rare cases of unstable hemoglobins with severe hemolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/616/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Suspecting the diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of a patient with an unstable hemoglobin variant is that of a slight to moderate, usually normocytic anemia that may be accompanied by splenomegaly. Clinical presentations include the following (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Clinical manifestations of unstable hemoglobins'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Congenital nonspherocytic hemolytic anemia with splenomegaly and pigmented (bilirubin) gallstones",
"     </li>",
"     <li>",
"      Heinz body hemolytic anemia with sensitivity to oxidant drugs",
"     </li>",
"     <li>",
"      Anemia with reticulocytosis out of proportion to the level of circulating hemoglobin",
"     </li>",
"     <li>",
"      A thalassemia-like peripheral blood picture",
"     </li>",
"     <li>",
"      Increased formation of methemoglobin",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Making the diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of an unstable hemoglobin variant is established by the detection of Heinz bodies in red cells, the demonstration of hemoglobin instability in the red cell hemolysate, and the presence of pigmenturia. The definitive diagnosis is established by documenting the causative mutation in the patient&rsquo;s DNA. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Diagnosis'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H19\">",
"     'Differential diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of patients with an unstable hemoglobin variant is mainly supportive, including the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    supplementation, transfusion when required, and, in occasional patients, splenectomy. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Treatment'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Nagel RL. Unstable hemoglobins; hemoglobins with altered O2 affinity; Hb M. In: Disorders of Hemoglobin: Genetics, Pathophysiology, Clinical Management, Steinberg MH, Forget BG, Higgs DR, et al. (Eds), Cambridge University Press, Cambridge 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/616/abstract/2\">",
"      Miller DR, Weed RI, Stamatoyannopoulos G, Yoshida A. Hemoglobin K&ouml;ln disease occurring as a fresh mutation: erythrocyte metabolism and survival. Blood 1971; 38:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/616/abstract/3\">",
"      Levine RL, Lincoln DR, Buchholz WM, et al. Hemoglobin Hasharon in a premature infant with hemolytic anemia. Pediatr Res 1975; 9:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/616/abstract/4\">",
"      Lee-Potter JP, Deacon-Smith RA, Simpkiss MJ, et al. A new cause of haemolytic anaemia in the newborn. A description of an unstable fetal haemoglobin: F Poole, alpha2-G-gamma2 130 trptophan yeilds glycine. J Clin Pathol 1975; 28:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/616/abstract/5\">",
"      Zinkham WH, Winslow RM. Unstable hemoglobins: influence of environment on phenotypic expression of a genetic disorder. Medicine (Baltimore) 1989; 68:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/616/abstract/6\">",
"      Lode HN, Krings G, Schulze-Neick I, et al. Pulmonary hypertension in a case of Hb-Mainz hemolytic anemia. J Pediatr Hematol Oncol 2007; 29:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/616/abstract/7\">",
"      Eisinger J, Flores J, Tyson JA, Shohet SB. Fluorescent cytoplasm and Heinz bodies of hemoglobin K&ouml;ln erythrocytes: evidence for intracellular heme catabolism. Blood 1985; 65:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/616/abstract/8\">",
"      Tucker PW, Phillips SE, Perutz MF, et al. Structure of hemoglobins Z&uuml;rich [His E7(63)beta replaced by Arg] and Sydney [Val E11(67)beta replaced by Ala] and role of the distal residues in ligand binding. Proc Natl Acad Sci U S A 1978; 75:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/616/abstract/9\">",
"      Virshup DM, Zinkham WH, Sirota RL, Caughey WS. Unique sensitivity of Hb Z&uuml;rich to oxidative injury by phenazopyridine: reversal of the effects by elevating carboxyhemoglobin levels in vivo and in vitro. Am J Hematol 1983; 14:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/616/abstract/10\">",
"      Zinkham WH, Houtchens RA, Caughey WS. Relation between variations in the phenotypic expression of an unstable hemoglobin disorder (hemoglobin Z&uuml;rich) and carboxyhemoglobin levels. Am J Med 1983; 74:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/616/abstract/11\">",
"      Schl&uuml;ter K, Drenckhahn D. Co-clustering of denatured hemoglobin with band 3: its role in binding of autoantibodies against band 3 to abnormal and aged erythrocytes. Proc Natl Acad Sci U S A 1986; 83:6137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/616/abstract/12\">",
"      Moo-Penn WF, Jue DL, Johnson MH, et al. Hemoglobin Brockton [beta 138 (H16) Ala----Pro]: an unstable variant near the C-terminus of the beta-subunits with normal oxygen-binding properties. Biochemistry 1988; 27:7614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/616/abstract/13\">",
"      Coleman MB, Steinberg MH, Adams JG 3rd. Hemoglobin Terre Haute arginine beta 106. A posthumous correction to the original structure of hemoglobin Indianapolis. J Biol Chem 1991; 266:5798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/616/abstract/14\">",
"      Adams JG 3rd, Boxer LA, Baehner RL, et al. Hemoglobin Indianapolis (beta 112[G14] arginine). An unstable beta-chain variant producing the phenotype of severe beta-thalassemia. J Clin Invest 1979; 63:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/616/abstract/15\">",
"      Honig GR, Shamsuddin M, Zaizov R, et al. Hemoglobin Petah Tikva (alpha 110 ala replaced by asp): a new unstable variant with alpha-thalassemia-like expression. Blood 1981; 57:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/616/abstract/16\">",
"      Kano G, Morimoto A, Hibi S, et al. Hb Bristol-Alesha presenting thalassemia-type hyperunstable hemoglobinopathy. Int J Hematol 2004; 80:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/616/abstract/17\">",
"      Rachmilewitz EA, Harari E. Intermediate hemichrome formation after oxidation of three unstable hemoglobins (Freiburg, Riverdale-Bronx and K&ouml;ln). Hamatol Bluttransfus 1972; 10:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/616/abstract/18\">",
"      Winterbourn CC, Carrell RW. Studies of hemoglobin denaturation and Heinz body formation in the unstable hemoglobins. J Clin Invest 1974; 54:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/616/abstract/19\">",
"      Fischer S, Nagel RL, Bookchin RM, et al. The binding of hemoglobin to membranes of normal and sickle erythrocytes. Biochim Biophys Acta 1975; 375:422.",
"     </a>",
"    </li>",
"    <li>",
"     Low P. Interaction of native and denatured hemoglobins with band 3: Consequences for erythrocyte structure and function. In: Red Blood Cell Membranes: Structure, Function, Clinical Implications, Agre P, Parker JC (Eds), Marcel Dekker, New York 1989.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/616/abstract/21\">",
"      Walder JA, Chatterjee R, Steck TL, et al. The interaction of hemoglobin with the cytoplasmic domain of band 3 of the human erythrocyte membrane. J Biol Chem 1984; 259:10238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/616/abstract/22\">",
"      Greenberg MS. Heinz body hemolytic animea. \"Bite cells\" -a clue to diagnosis. Arch Intern Med 1976; 136:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/616/abstract/23\">",
"      Sen U, Dasgupta J, Choudhury D, et al. Crystal structures of HbA2 and HbE and modeling of hemoglobin delta 4: interpretation of the thermal stability and the antisickling effect of HbA2 and identification of the ferrocyanide binding site in Hb. Biochemistry 2004; 43:12477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/616/abstract/24\">",
"      Bain BJ. Heinz body haemolytic anaemia in Wilson's disease. Br J Haematol 1999; 104:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/616/abstract/25\">",
"      Nagel RL, Ranney HM. Drug-induced oxidative denaturation of hemoglobin. Semin Hematol 1973; 10:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/616/abstract/26\">",
"      Perutz MF, Raidt H. Stereochemical basis of heat stability in bacterial ferredoxins and in haemoglobin A2. Nature 1975; 255:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/616/abstract/27\">",
"      GRIMES AJ, MEISLER A, DACIE JV. CONGENITAL HEINZ-BODY ANAEMIA. FURTHER EVIDENCE ON THE CAUSE OF HEINZ-BODY PRODUCTION IN RED CELLS. Br J Haematol 1964; 10:281.",
"     </a>",
"    </li>",
"    <li>",
"     Nagel RL, Jaffe E. Dyshemoglobins. In: Disorders of Hemoglobin: Genetics, Pathophysiology, Clinical Management, Steinberg MH, Forget BG, Higgs DR, et al. (Eds), Cambridge UP, Cambridge 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/616/abstract/29\">",
"      Richards FM. Protein stability: still an unsolved problem. Cell Mol Life Sci 1997; 53:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/616/abstract/30\">",
"      Perutz MF. Electrostatic effects in proteins. Science 1978; 201:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/616/abstract/31\">",
"      Carrell RW, Kay R. A simple method for the detection of unstable haemoglobins. Br J Haematol 1972; 23:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/616/abstract/32\">",
"      Asakura T, Adachi K, Shapiro M, et al. Mechanical precipitation of hemoglobin k&ouml;ln. Biochim Biophys Acta 1975; 412:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/616/abstract/33\">",
"      Roth EF Jr, Elbaum D, Bookchin RM, Nagel RL. The conformational requirements for the mechanical precipitation of hemoglobin S and other mutants. Blood 1976; 48:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/616/abstract/34\">",
"      Crary SE, Buchanan GR. Vascular complications after splenectomy for hematologic disorders. Blood 2009; 114:2861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/616/abstract/35\">",
"      Rose C, Bauters F, Galacteros F. Hydroxyurea therapy in highly unstable hemoglobin carriers. Blood 1996; 88:2807.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7086 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-190.92.87.115-B12D491B22-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_38_616=[""].join("\n");
var outline_f0_38_616=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS OF UNSTABLE HEMOGLOBINS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Hemolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pigmenturia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOPHYSIOLOGY OF UNSTABLE HEMOGLOBINS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Mutations that weaken or modify the heme-globin interactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Hb Zurich",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Hb K&ouml;ln",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Mutations that interfere with the secondary structure of the subunits",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Mutations that interfere with the tertiary structure of the subunit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Mutations that affect subunit interactions: interference with the quaternary structure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Hyperunstable hemoglobins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Heinz body formation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Mechanisms of anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      INSTABILITY OF COMMON HEMOGLOBINS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Hemoglobin A2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Hemoglobin E",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Peripheral blood smear and Heinz body preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Hemoglobin studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Stability tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Splenectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Suspecting the diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Making the diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7086\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7086|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/43/10933\" title=\"figure 1\">",
"      Mutations in heme pocket",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7086|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/28/26054\" title=\"picture 1\">",
"      Heinz body hemolytic anemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/54/22377?source=related_link\">",
"      Clinical manifestations and pathogenesis of human parvovirus B19 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/46/4841?source=related_link\">",
"      Genetics and pathogenesis of methemoglobinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/1/20506?source=related_link\">",
"      Hereditary spherocytosis: Clinical features; diagnosis; and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/60/968?source=related_link\">",
"      Laboratory diagnosis of the hemoglobinopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/58/9129?source=related_link\">",
"      Molecular pathology of the thalassemic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/29/23001?source=related_link\">",
"      Structure and function of normal human hemoglobins",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_38_617="Parainfluenza viruses in adults";
var content_f0_38_617=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Parainfluenza viruses in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/38/617/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/38/617/contributors\">",
"     Michael G Ison, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/38/617/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/38/617/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/38/617/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/38/617/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/38/617/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parainfluenza viruses are important respiratory pathogens in adults and children. Although parainfluenza viruses are commonly recognized as a significant cause of morbidity and mortality in children, their impact in adults is less well characterized [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/1\">",
"     1",
"    </a>",
"    ]. In adults, parainfluenza viruses usually cause mild upper respiratory infections but can lead to life-threatening lower respiratory tract infections, particularly in immunocompromised patients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The virology, clinical manifestations, diagnosis, and treatment of parainfluenza viruses in adults will be reviewed here. Infection with parainfluenza viruses in children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36808?source=see_link\">",
"     \"Parainfluenza viruses in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     VIROLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parainfluenza viruses (PIVs) are single-stranded, enveloped RNA viruses belonging to the genus paramyxovirus in the Paramyxoviridae family [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/3\">",
"     3",
"    </a>",
"    ]. This family also includes mumps, measles, respiratory syncytial viruses, human metapneumovirus, and Nipah and Hendra viruses [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Structure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parainfluenza virions are pleomorphic, range in diameter from 150 to 200 microns, and contain approximately 15,500 nucleotides [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/4\">",
"     4",
"    </a>",
"    ]. The single strand of negative-sense RNA encodes the following viral proteins: nucleocapsid protein (N), phosphoprotein (P), matrix protein (M), fusion glycoprotein (F), hemagglutinin-neuraminidase glycoprotein (HN), and polymerase (L) (",
"    <a class=\"graphic graphic_figure graphicRef80809 \" href=\"UTD.htm?30/49/31505\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/4\">",
"     4",
"    </a>",
"    ]. In addition, serotype PIV-3 encodes C, D, and V proteins; PIV-1 encodes a C protein; and PIV-2 encodes a V protein.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The HN and F proteins project through the lipid envelope and form the major antigenic targets for neutralizing antibody [",
"      <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The nucleocapsid core is composed of N, P, and L proteins in association with viral RNA. N proteins bind tightly to the viral genome, creating a template for the RNA polymerase composed of the P and L proteins [",
"      <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The HN glycoproteins are involved in attachment of the virus to the host cell via interactions with sialic acid residues on the cell surface [",
"      <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/9\">",
"       9",
"      </a>",
"      ]. This interaction allows the F protein to mediate virus-cell membrane fusion, which is required for nucleocapsid entry and infection of the host cell. The neuraminidase portion of the HN protein mediates budding of progeny virions from the surface of infected cells [",
"      <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/9,10\">",
"       9,10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The HN glycoproteins of PIVs are more antigenically stable than those of influenza A viruses. However, the development of antigenic differences over time has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/11\">",
"     11",
"    </a>",
"    ], which may interfere with the production of an effective vaccine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15272?source=see_link\">",
"     \"Epidemiology of influenza\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Serotypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Four major serotypes of human PIVs (PIV-1, -2, -3, -4) have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/1,5,6\">",
"     1,5,6",
"    </a>",
"    ]. PIV-1 and -3 are members of the Respirovirus genera, whereas PIV-2 and -4 are members of the Rubulavirus genera [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/6\">",
"     6",
"    </a>",
"    ]. The classification of the parainfluenza viruses into two genera is based upon genetic characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations vary depending upon the viral serotype, as discussed below. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Clinical manifestations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parainfluenza viruses initially infect epithelial cells of the nose and oropharynx and then spread distally to the large and small airways [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/12\">",
"     12",
"    </a>",
"    ]. Significant viral replication occurs in the nose and lungs 24 hours after infection, with viral replication peaking after two to five days [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/13\">",
"     13",
"    </a>",
"    ]. Viral antigen can be detected in the apical portion of respiratory epithelial cells from days one to six of infection with a decrease on day seven [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The extent of infection correlates well with the severity of disease: mild upper respiratory tract infections are associated with limited infection of the nasopharynx, whereas more severe disease involves spread of infection to the large and small airways [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. PIV-1 and PIV-2, which are associated with croup, usually infect the larynx and upper trachea, whereas PIV-3, which is associated with bronchiolitis and pneumonia, infects the distal airways [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pathologic examination of infected tissues in animal models of PIV infection suggests that minimal cellular damage results from direct viral effects [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/14\">",
"     14",
"    </a>",
"    ]. As is the case with other respiratory viruses, the host immune response is likely to play an important role in the pathogenesis of PIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/13\">",
"     13",
"    </a>",
"    ]. The increase in airway responsiveness that is often associated with PIV-3 infection (and other respiratory viruses such as respiratory syncytial virus) may result from increased stromal interleukin-11 production, enhanced acetylcholine release, and increased release of leukotrienes [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/17-19\">",
"     17-19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human parainfluenza viruses are a common cause of respiratory tract infection, and spread within families is extensive, requiring person-to-person contact or large droplet inhalation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/20\">",
"     20",
"    </a>",
"    ]. By adulthood, more than 90 percent of individuals have antibodies to PIV, although they are only partially protective against subsequent infection. Even in the presence of high levels of serotype-specific antibodies, primary infection and reinfection can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36808?source=see_link\">",
"     \"Parainfluenza viruses in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Seasonality",
"    </span>",
"    &nbsp;&mdash;&nbsp;PIV infections occur throughout the world and throughout the year, with certain serotypes predominating during the spring or fall. In the United States, PIV-1 usually causes outbreaks biennially during the fall of odd-numbered years (",
"    <a class=\"graphic graphic_figure graphicRef56691 \" href=\"UTD.htm?16/28/16834\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. In contrast, PIV-2 occurs in annual epidemics in the fall [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/21\">",
"     21",
"    </a>",
"    ]. PIV-3 is the least predictable and is endemic, but outbreaks in the spring do occur [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/5,21\">",
"     5,21",
"    </a>",
"    ]. Seasonal patterns of PIV-4 infections have not been established since the disease is usually mild and the virus is difficult to detect. In tropical countries, parainfluenza viruses do not exhibit seasonal variation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Trends in PIV infections in the United States are monitored by the National Respiratory and Enteric Virus Surveillance System and can be found on the website of the Centers for Disease Control and Prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Serotype prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;PIV-3 is the most prevalent serotype in both children and adults and is associated with pneumonia and bronchiolitis; bronchiolitis is typically only seen in children. PIV-1 and -2 are detected less frequently in adults and are usually associated with upper respiratory tract infection, although lower tract disease has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/2,6,25\">",
"     2,6,25",
"    </a>",
"    ]. PIV-4 usually causes mild upper respiratory tract infection in both adults and children and, because of its rarity, is less well characterized than the other PIVs [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Clinical manifestations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In a surveillance study of PIVs in children and adults in the United States from 1990 to 2004 in which more than 40,000 cases were detected, the serotypes were found in the following proportions [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      PIV-3 &ndash; 52 percent",
"     </li>",
"     <li>",
"      PIV-1 &ndash; 26 percent",
"     </li>",
"     <li>",
"      PIV-2 &ndash; 12 percent",
"     </li>",
"     <li>",
"      PIV-4 &ndash; 2 percent",
"     </li>",
"     <li>",
"      Uncharacterized serotype &ndash; 8 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Severe disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among adults, PIV infections typically cause mild upper respiratory tract infections but can cause pneumonia, particularly in immunocompromised hosts such as hematopoietic cell transplant (HCT) recipients, patients with leukemia, and, less commonly, solid organ transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/27-30\">",
"     27-30",
"    </a>",
"    ]. Immunocompromise also increases the risk of severe PIV infection. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Clinical manifestations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H663929612\">",
"    <span class=\"h2\">",
"     Outbreaks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outbreaks among elderly individuals in long-term care facilities have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. Nosocomial PIV outbreaks have also occurred among HCT recipients. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Immunocompromised hosts'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical findings depend upon the host immune status and the PIV serotype. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Serotype prevalence'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Most adults with PIV infection present with nonspecific findings such as fever, rhinorrhea, cough,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sore throat [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/25\">",
"     25",
"    </a>",
"    ]. The clinical manifestations of PIV in children are better characterized, with croup or laryngotracheobronchitis as the classic finding of PIV-1 infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36808?source=see_link&amp;anchor=H10#H10\">",
"     \"Parainfluenza viruses in children\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Immunocompetent hosts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among immunocompetent adults, PIV infections are usually asymptomatic or mild, self-limited upper respiratory tract infections [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/1\">",
"     1",
"    </a>",
"    ]. Of the parainfluenza viruses, PIV-3 followed by PIV-1 and -2 are most commonly associated with lower tract disease, whereas PIV-4 is usually associated with mild upper respiratory tract disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/6,26\">",
"     6,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PIV is associated with one to 15 percent of acute respiratory illness in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/25\">",
"     25",
"    </a>",
"    ]. The risk of severe PIV disease is highest among elderly individuals, particularly debilitated nursing home residents. In one study, between 4 and 14 percent of nursing home residents had a respiratory illness attributable to PIV [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PIVs are responsible for approximately 2 to 6 percent of cases of community-acquired pneumonia (CAP) in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. In one study, patients with CAP caused by a respiratory virus, including PIV, were more likely to be older, frailer, or have cardiac disease compared with patients with a bacterial etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/34\">",
"     34",
"    </a>",
"    ]. Fatal cases and outbreaks of PIV infection in long-term care facilities have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/25,31-33\">",
"     25,31-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PIV infection is associated with exacerbations of asthma and chronic obstructive pulmonary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/19,37,38\">",
"     19,37,38",
"    </a>",
"    ]. Otitis media and sinusitis can occur as either primary PIV infections or secondary bacterial superinfections [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/39\">",
"     39",
"    </a>",
"    ]. Nonrespiratory complications of PIV are rare but include meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/40\">",
"     40",
"    </a>",
"    ], myocarditis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pericarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/41\">",
"     41",
"    </a>",
"    ], and Guillain-Barr&eacute; syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Immunocompromised hosts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parainfluenza viruses cause significant morbidity and mortality among immunocompromised adults [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/2\">",
"     2",
"    </a>",
"    ]. The highest morbidity and mortality has been described in hematopoietic cell transplant (HCT) recipients, patients with leukemia, and solid organ transplant recipients, particularly lung transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/26,28,29,43-45\">",
"     26,28,29,43-45",
"    </a>",
"    ]. PIV infections have also been described in HIV-infected individuals and patients with malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/26,30,46\">",
"     26,30,46",
"    </a>",
"    ]. In one study, the mortality rate associated with PIV infection was higher in HIV-infected children than in children without HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies of respiratory viruses in immunocompromised patients have traditionally focused on patients hospitalized with respiratory symptoms; this may underestimate the incidence and overestimate the severity of disease caused by PIVs [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/2\">",
"     2",
"    </a>",
"    ]. More recent studies have estimated the incidence of symptomatic PIV infection to be 2 to 7 percent in HCT recipients and approximately 5 percent in lung transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/26,28,29,48,49\">",
"     26,28,29,48,49",
"    </a>",
"    ]. Most cases appear to be community-acquired, but outbreaks in HCT units have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/28,50,51\">",
"     28,50,51",
"    </a>",
"    ]. PIV-3 is the serotype most frequently isolated from immunocompromised patients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a retrospective cohort study that included &gt;3500 HCT recipients at a single center, PIV infections occurred in 253 patients (7 percent) who developed respiratory symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/28\">",
"     28",
"    </a>",
"    ]. PIV-3 occurred in 90 percent, followed by PIV-1 in 6 percent, PIV-2 in 4 percent, and PIV-4 in one patient. At presentation, 198 of 228 patients (87 percent) with PIV-3 infection had upper respiratory tract involvement only, whereas 13 (6 percent) had evidence of upper and lower tract disease, and 17 (7 percent) had pneumonitis in the absence of upper respiratory tract symptoms. Twenty-five patients (13 percent) with upper tract disease progressed to lower tract disease a median of three days after developing upper respiratory tract symptoms. Glucocorticoids were associated in a dose-dependent manner with increased risk of progression from upper to lower tract disease and mortality. Mortality was high: 35 percent at 30 days and 75 percent at 180 days. Pulmonary copathogens were isolated from 29 of 55 patients (53 percent) with PIV-3 pneumonia.",
"   </p>",
"   <p>",
"    Another retrospective study evaluated PIV infections in 200 patients who had either undergone HCT or had leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/30\">",
"     30",
"    </a>",
"    ]. At initial presentation, most patients (70 percent) had only an upper respiratory tract infection, and the remainder (30 percent) had pneumonia. Independent risk factors for progression to pneumonia included neutropenia, an APACHE II score &gt;15, and respiratory coinfections. The overall mortality rate 30 days following diagnosis was 9 percent, whereas the mortality rate among patients with PIV pneumonia was 17 percent. Mortality rates were similar in HCT recipients and in those with leukemia. Independent predictors of death were relapsed or refractory underlying malignancy, APACHE II score &gt;15, and high-dose glucocorticoid use. &nbsp;",
"   </p>",
"   <p>",
"    In addition to causing upper and lower respiratory tract infections, PIVs are also associated with asymptomatic shedding among HCT recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/48\">",
"     48",
"    </a>",
"    ]. In a prospective study that followed patients for 100 days following HCT, 17 of 122 individuals (18 percent) were found to have PIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/48\">",
"     48",
"    </a>",
"    ]. Of these, six individuals had asymptomatic shedding.",
"   </p>",
"   <p>",
"    PIV infections among both HCT and lung transplant recipients have been associated with significant short- and long-term pulmonary dysfunction. PIVs have been associated with acute rejection in lung transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/29,43,52\">",
"     29,43,52",
"    </a>",
"    ]. Animal models of a related virus, Sendai virus, suggest that there is a complex interplay between direct viral cytopathic effects and local induction of inflammation that contribute to acute rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. In lung transplant recipients, PIVs, particularly those causing lower tract infection, are associated with bronchiolitis obliterans syndrome, a form of chronic rejection in this population [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/29,43,52,55,56\">",
"     29,43,52,55,56",
"    </a>",
"    ]. Among HCT recipients, PIV infection is associated with an 18-fold increase in the risk of developing severe airflow decline during the first posttransplant year [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with PIV pneumonia, high-resolution chest computed tomography may reveal interstitial infiltrates, ground glass opacities,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    airspace consolidations, which are indistinguishable from findings noted with other viral and non-viral pathogens. In addition, small peribronchial nodules have been seen in some cases (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68781 \" href=\"UTD.htm?9/38/9830\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/58\">",
"     58",
"    </a>",
"    ]. Such nodules are not specific for PIV; they may also occur with a variety of other infectious (eg, fungi, bacteria, higher order bacteria such as Nocardia and Actinomyces, viruses) and noninfectious causes. Thus, appropriate studies should be done to rule out alternative pathogens, since bacterial and fungal pathogens often complicate PIV infections in immunocompromised patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no clinical features that are pathognomonic for parainfluenza virus infection. Local surveillance for PIV infection is not routinely done (although trends are monitored as part of the National Respiratory and Enteric Virus Surveillance System [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/24\">",
"     24",
"    </a>",
"    ]), and cocirculation with other pathogens makes clinical diagnosis challenging. As a result, microbiologic tests are required when it is important to establish a definitive diagnosis. Since there is no specific treatment available for PIV infection, it is not necessary to make a microbiologic diagnosis for most immunocompetent patients.",
"   </p>",
"   <p>",
"    Viral culture of nasal washings or swabs or bronchoalveolar lavage fluid has traditionally been the gold standard for diagnosing PIV infection. Antigen detection tests are also commonly used in hospital laboratories, although they have limited sensitivity and are not available as a rapid antigen kit. PCR is becoming increasingly available and has higher sensitivity than either viral culture or antigen detection assays. Serology has a limited role for the diagnosis of PIV infection.",
"   </p>",
"   <p>",
"    Nasal washings have a higher sensitivity than nasal swabs for the detection of respiratory viruses, including PIVs, regardless of the method of detection [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/59\">",
"     59",
"    </a>",
"    ]. PIVs are stable in viral transport media at 4&ordm;C for up to five days. Samples should not be held at room temperature since the virus loses viability within one hour [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Approach to diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral culture",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    antigen detection assays are the most common modalities used for the diagnosis of PIV infection. However, given that PCR has higher sensitivity than either of these methods, we favor it for the diagnosis of PIV infection in immunocompromised patients in whom establishing the diagnosis is most important. If available, multiplex PCR has the further advantage of being able to test for multiple possible etiologies simultaneously.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preferred cell lines for PIV culture are monkey kidney cell lines (eg, LLC-MK2), but commercially available mixed cell culture systems will support growth as well [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/5,60\">",
"     5,60",
"    </a>",
"    ]. Hemadsorption inhibition, hemagglutination inhibition, or immunofluorescence is used to identify PIV in culture [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A centrifugation-enhanced shell vial assay that uses monoclonal antibodies for the detection of PIVs grown in cell culture increases sensitivity and can provide results more quickly than traditional culture techniques, often within 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/61\">",
"     61",
"    </a>",
"    ]. Traditional viral culture typically takes 5 to 14 days [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/5\">",
"     5",
"    </a>",
"    ]. Thus, culture using the shell vial technique is preferred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Antigen detection",
"    </span>",
"    &nbsp;&mdash;&nbsp;No rapid antigen kit is available for the detection of PIVs. However, reagents for the detection of PIV antigen by direct or indirect fluorescence antibody testing of nasal specimens (washings or swabs) or bronchoalveolar lavage fluid are available, although the sensitivity is limited, ranging from 70 to 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/5,60\">",
"     5,60",
"    </a>",
"    ]. Specificity is at least 94 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/5\">",
"     5",
"    </a>",
"    ]. The primary benefit of antigen detection is the ability to establish a diagnosis quickly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Polymerase chain reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCR has the highest yield for the detection of PIV, particularly in immunocompromised patients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/48,62,63\">",
"     48,62,63",
"    </a>",
"    ]. Compared with culture, PCR has a sensitivity of 100 percent and a specificity of 95 to 98 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/64,65\">",
"     64,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PCR primers are usually directed toward the hemagglutinin-neuraminidase gene although they differ among assays [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/5,66\">",
"     5,66",
"    </a>",
"    ]. Multiplex PCR assays have been developed that are able to identify and differentiate between a wide variety of respiratory pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/65-68\">",
"     65-68",
"    </a>",
"    ]. If available, use of multiplex molecular assays applied to nasal swabs or washings or bronchoalveolar lavage fluid should be used for the diagnosis of infection in immunocompromised patients.",
"   </p>",
"   <p>",
"    Drawbacks of PCR are that it is not widely available as an in-house test and it generally takes longer to obtain results compared with antigen detection assays. However, newer commercially available assays may increase local availability over time. Unlike antigen detection tests that can be performed on a sample-by-sample basis, specimens for PCR are usually batched and processed only on certain days in hospital laboratories, whereas sending a sample to a commercial laboratory often results in a minimum of 24 hours for a result to be reported. Caution should be used when using some of the available multiplex molecular assays since reduced sensitivity for some PIV subtypes has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/69-71\">",
"     69-71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serology is not practical since the diagnosis of PIV infection is usually established by comparing acute and convalescent sera, the latter of which is obtained approximately two weeks following acute infection [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Diagnosis by serology requires a four-fold rise in IgG titer between the acute and convalescent samples, or the appearance of an IgM response [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no antiviral agents with proven efficacy for PIV infections. Thus, the mainstay of therapy for PIV infection in immunocompromised hosts is reduction of immunosuppression, particularly reduction in the dose of glucocorticoid when possible [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Case reports and small case series have shown variable results for the use of aerosolized, oral, or intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    for the treatment of PIV infection in HCT and solid organ transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/27,28,72-75\">",
"     27,28,72-75",
"    </a>",
"    ]. The largest of these was a retrospective study in which 31 of 55 HCT recipients with PIV pneumonia received aerosolized ribavirin with or without intravenous immunoglobulin; treatment did not reduce viral shedding or mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/28\">",
"     28",
"    </a>",
"    ]. Given the lack of proven benefit with ribavirin or intravenous immunoglobulin, we suggest",
"    <strong>",
"     not",
"    </strong>",
"    using these agents.",
"   </p>",
"   <p>",
"    Development of effective antiviral agents for the treatment of PIV in immunocompromised hosts is needed. Two hemagglutinin-neuraminidase inhibitors have been developed that have potent in vitro and in vivo activity against PIV [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. A recombinant sialidase fusion protein, DAS181, has also been shown to inhibit human PIV infection via enzymatic removal of the sialic acid moiety of PIV receptors in cell cultures, human airway epithelial tissue cultures, and in a cotton rat model [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/78\">",
"     78",
"    </a>",
"    ]. In addition, three transplant recipients with severe PIV infection have been given DAS181; treatment was well-tolerated and was temporally associated with improvement in symptoms, oxygenation, and pulmonary function, as well as a reduction in PIV viral load from nasopharyngeal specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. It is available for compassionate use from the manufacturer. &nbsp;",
"   </p>",
"   <p>",
"    The benefit of intravenous immunoglobulin has not been proven in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/28\">",
"     28",
"    </a>",
"    ], although studies in rats have shown a decrease in PIV titers when human PIV immunoglobulin or convalescent rat serum was administered intranasally [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Short interfering RNAs (siRNAs) have been shown to prevent infection in mice [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/82\">",
"     82",
"    </a>",
"    ]. Although siRNAs have not been tested in humans, there is interest in studying their utility for the treatment of human PIV infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Vaccine development",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no licensed vaccine to prevent infection with parainfluenza viruses, although vaccine development is underway. Natural immunity to PIV is incomplete and reinfection is common. Thus, a protective PIV vaccine may have value, particularly among children and immunocompromised individuals. Vaccine development is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36808?source=see_link&amp;anchor=H13#H13\">",
"     \"Parainfluenza viruses in children\", section on 'Vaccine development'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Infection control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hospitalized patients with PIV infection should be placed on standard and contact precautions, and should have a private room whenever possible [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/617/abstract/83\">",
"     83",
"    </a>",
"    ]. Respiratory precautions are not necessary, because the droplets are large and do not aerosolize. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=see_link\">",
"     \"General principles of infection control\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In adults, parainfluenza viruses usually cause mild upper respiratory infections but can lead to life-threatening lower respiratory tract infections, particularly in immunocompromised and elderly patients. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Parainfluenza viruses (PIVs) are single-stranded, enveloped RNA viruses belonging to the genus paramyxovirus. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Virology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The extent of infection correlates well with the severity of disease: mild upper respiratory tract infections are associated with limited infection of the nasopharynx, whereas more severe disease involves spread of infection to the large and small airways. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the United States, serotype PIV-1 usually causes outbreaks biennially during the fall of odd-numbered years. In contrast, PIV-2 and PIV-3 occur in annual epidemics in the fall and spring, respectively. In tropical countries, parainfluenza viruses do not exhibit seasonal variation. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among immunocompetent adults, PIV infections are usually asymptomatic or mild, self-limited upper respiratory tract infections, whereas in immunocompromised patients, PIV infections cause pneumonia in a substantial proportion, particularly in hematopoietic cell transplant recipients. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Viral culture",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      antigen detection assays are the most common modalities used for the diagnosis of PIV infection. However, we favor PCR for the diagnosis of PIV infection in immunocompromised patients with lower respiratory tract disease, in whom establishing the diagnosis is most important. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no antiviral agents with proven efficacy for PIV infections. &nbsp;We suggest",
"      <strong>",
"       not",
"      </strong>",
"      using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      or intravenous immunoglobulin for the treatment of parainfluenza virus pneumonia given the lack of proven benefit (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no licensed vaccine to prevent infection with parainfluenza viruses, although vaccine development is underway. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Vaccine development'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hospitalized patients with PIV infection should be placed on standard and contact precautions, and should have a private room whenever possible. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Infection control'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/1\">",
"      Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med 2001; 344:1917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/2\">",
"      Ison MG. Respiratory viral infections in transplant recipients. Antivir Ther 2007; 12:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/3\">",
"      Lambert DM, Barney S, Lambert AL, et al. Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. Proc Natl Acad Sci U S A 1996; 93:2186.",
"     </a>",
"    </li>",
"    <li>",
"     Karron, RA, Collins, PL. Parainfluenza Viruses. In: Fields Virology, 5th Edition, Knipe, D, Howley, P (Eds), Lippincott Williams and Wilkins, Philadelphia 2006. p. 1497.",
"    </li>",
"    <li>",
"     Piedra, PA, Glezen, WP. Respiratory Syncytial Virus and Parainfluenza Viruses. In: Clinical Virology, 2nd edition, Richman, DD, Whitley, RJ, Hayden, FG (Eds), ASM Press, Washington, DC 2002. p. 763.",
"    </li>",
"    <li>",
"     Wright, PF. Parainfluenza Viruses. In: Principles and Practice of Infectious Diseases, 6th edition, Mandell, GL, Bennett, JE, Dolin, R (Eds), Elsevier Churchill Livingstone, Philadelphia 2005. p. 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/7\">",
"      Tao T, Durbin AP, Whitehead SS, et al. Recovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin-neuraminidase and fusion glycoproteins have been replaced by those of PIV type 1. J Virol 1998; 72:2955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/8\">",
"      Hamaguchi M, Yoshida T, Nishikawa K, et al. Transcriptive complex of Newcastle disease virus. I. Both L and P proteins are required to constitute an active complex. Virology 1983; 128:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/9\">",
"      Moscona A. Interaction of human parainfluenza virus type 3 with the host cell surface. Pediatr Infect Dis J 1997; 16:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/10\">",
"      Huberman K, Peluso RW, Moscona A. Hemagglutinin-neuraminidase of human parainfluenza 3: role of the neuraminidase in the viral life cycle. Virology 1995; 214:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/11\">",
"      Henrickson KJ, Savatski LL. Genetic variation and evolution of human parainfluenza virus type 1 hemagglutinin neuraminidase: analysis of 12 clinical isolates. J Infect Dis 1992; 166:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/12\">",
"      Castleman WL, Brundage-Anguish LJ, Kreitzer L, Neuenschwander SB. Pathogenesis of bronchiolitis and pneumonia induced in neonatal and weanling rats by parainfluenza (Sendai) virus. Am J Pathol 1987; 129:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/13\">",
"      Porter DD, Prince GA, Hemming VG, Porter HG. Pathogenesis of human parainfluenza virus 3 infection in two species of cotton rats: Sigmodon hispidus develops bronchiolitis, while Sigmodon fulviventer develops interstitial pneumonia. J Virol 1991; 65:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/14\">",
"      Prince GA, Porter DD. Treatment of parainfluenza virus type 3 bronchiolitis and pneumonia in a cotton rat model using topical antibody and glucocorticosteroid. J Infect Dis 1996; 173:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/15\">",
"      Welliver RC, Wong DT, Middleton E Jr, et al. Role of parainfluenza virus-specific IgE in pathogenesis of croup and wheezing subsequent to infection. J Pediatr 1982; 101:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/16\">",
"      Welliver RC, Wong DT, Sun M, McCarthy N. Parainfluenza virus bronchiolitis. Epidemiology and pathogenesis. Am J Dis Child 1986; 140:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/17\">",
"      Einarsson O, Geba GP, Zhu Z, et al. Interleukin-11: stimulation in vivo and in vitro by respiratory viruses and induction of airways hyperresponsiveness. J Clin Invest 1996; 97:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/18\">",
"      Jacoby DB, Xiao HQ, Lee NH, et al. Virus- and interferon-induced loss of inhibitory M2 muscarinic receptor function and gene expression in cultured airway parasympathetic neurons. J Clin Invest 1998; 102:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/19\">",
"      Matsuse H, Kondo Y, Saeki S, et al. Naturally occurring parainfluenza virus 3 infection in adults induces mild exacerbation of asthma associated with increased sputum concentrations of cysteinyl leukotrienes. Int Arch Allergy Immunol 2005; 138:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/20\">",
"      Ansari SA, Springthorpe VS, Sattar SA, et al. Potential role of hands in the spread of respiratory viral infections: studies with human parainfluenza virus 3 and rhinovirus 14. J Clin Microbiol 1991; 29:2115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/21\">",
"      Fry AM, Curns AT, Harbour K, et al. Seasonal trends of human parainfluenza viral infections: United States, 1990-2004. Clin Infect Dis 2006; 43:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/22\">",
"      Marx A, T&ouml;r&ouml;k TJ, Holman RC, et al. Pediatric hospitalizations for croup (laryngotracheobronchitis): biennial increases associated with human parainfluenza virus 1 epidemics. J Infect Dis 1997; 176:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/23\">",
"      Chew FT, Doraisingham S, Ling AE, et al. Seasonal trends of viral respiratory tract infections in the tropics. Epidemiol Infect 1998; 121:121.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/surveillance/nrevss/human-paraflu/natl-trend.html/ (Accessed on November 24, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/25\">",
"      Falsey AR, Walsh EE. Viral pneumonia in older adults. Clin Infect Dis 2006; 42:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/26\">",
"      Kim YJ, Boeckh M, Englund JA. Community respiratory virus infections in immunocompromised patients: hematopoietic stem cell and solid organ transplant recipients, and individuals with human immunodeficiency virus infection. Semin Respir Crit Care Med 2007; 28:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/27\">",
"      Wendt CH, Weisdorf DJ, Jordan MC, et al. Parainfluenza virus respiratory infection after bone marrow transplantation. N Engl J Med 1992; 326:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/28\">",
"      Nichols WG, Corey L, Gooley T, et al. Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. Blood 2001; 98:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/29\">",
"      Vilchez RA, Dauber J, McCurry K, et al. Parainfluenza virus infection in adult lung transplant recipients: an emergent clinical syndrome with implications on allograft function. Am J Transplant 2003; 3:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/30\">",
"      Chemaly RF, Hanmod SS, Rathod DB, et al. The characteristics and outcomes of parainfluenza virus infections in 200 patients with leukemia or recipients of hematopoietic stem cell transplantation. Blood 2012; 119:2738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/31\">",
"      Parainfluenza infections in the elderly 1976-82. Br Med J (Clin Res Ed) 1983; 287:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/32\">",
"      Parainfluenza outbreaks in extended-care facilities -- United States. MMWR Morb Mortal Wkly Rep 1978; 27:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/33\">",
"      Glasgow KW, Tamblyn SE, Blair G. A respiratory outbreak due to parainfluenza virus type 3 in a home for the aged--Ontario. Can Commun Dis Rep 1995; 21:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/34\">",
"      Johnstone J, Majumdar SR, Fox JD, Marrie TJ. Viral infection in adults hospitalized with community-acquired pneumonia: prevalence, pathogens, and presentation. Chest 2008; 134:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/35\">",
"      Angeles Marcos M, Camps M, Pumarola T, et al. The role of viruses in the aetiology of community-acquired pneumonia in adults. Antivir Ther 2006; 11:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/36\">",
"      Diederen BM, Van Der Eerden MM, Vlaspolder F, et al. Detection of respiratory viruses and Legionella spp. by real-time polymerase chain reaction in patients with community acquired pneumonia. Scand J Infect Dis 2009; 41:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/37\">",
"      Johnston NW. The similarities and differences of epidemic cycles of chronic obstructive pulmonary disease and asthma exacerbations. Proc Am Thorac Soc 2007; 4:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/38\">",
"      Hansbro NG, Horvat JC, Wark PA, Hansbro PM. Understanding the mechanisms of viral induced asthma: new therapeutic directions. Pharmacol Ther 2008; 117:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/39\">",
"      Gwaltney JM Jr, Scheld WM, Sande MA, Sydnor A. The microbial etiology and antimicrobial therapy of adults with acute community-acquired sinusitis: a fifteen-year experience at the University of Virginia and review of other selected studies. J Allergy Clin Immunol 1992; 90:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/40\">",
"      Arisoy ES, Demmler GJ, Thakar S, Doerr C. Meningitis due to parainfluenza virus type 3: report of two cases and review. Clin Infect Dis 1993; 17:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/41\">",
"      Wilks D, Burns SM. Myopericarditis associated with parainfluenza virus type 3 infection. Eur J Clin Microbiol Infect Dis 1998; 17:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/42\">",
"      Rom&aacute;n G, Phillips CA, Poser CM. Parainfluenza virus type 3: isolation from CSF of a patient with Guillain-Barr&eacute; syndrome. JAMA 1978; 240:1613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/43\">",
"      Kumar D, Husain S, Chen MH, et al. A prospective molecular surveillance study evaluating the clinical impact of community-acquired respiratory viruses in lung transplant recipients. Transplantation 2010; 89:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/44\">",
"      Campbell AP, Chien JW, Kuypers J, et al. Respiratory virus pneumonia after hematopoietic cell transplantation (HCT): associations between viral load in bronchoalveolar lavage samples, viral RNA detection in serum samples, and clinical outcomes of HCT. J Infect Dis 2010; 201:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/45\">",
"      Weinberg A, Lyu DM, Li S, et al. Incidence and morbidity of human metapneumovirus and other community-acquired respiratory viruses in lung transplant recipients. Transpl Infect Dis 2010; 12:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/46\">",
"      Whimbey E, Bodey GP. Viral pneumonia in the immunocompromised adult with neoplastic disease: the role of common community respiratory viruses. Semin Respir Infect 1992; 7:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/47\">",
"      Madhi SA, Ramasamy N, Petersen K, et al. Severe lower respiratory tract infections associated with human parainfluenza viruses 1-3 in children infected and noninfected with HIV type 1. Eur J Clin Microbiol Infect Dis 2002; 21:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/48\">",
"      Peck AJ, Englund JA, Kuypers J, et al. Respiratory virus infection among hematopoietic cell transplant recipients: evidence for asymptomatic parainfluenza virus infection. Blood 2007; 110:1681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/49\">",
"      Nichols WG, Gooley T, Boeckh M. Community-acquired respiratory syncytial virus and parainfluenza virus infections after hematopoietic stem cell transplantation: the Fred Hutchinson Cancer Research Center experience. Biol Blood Marrow Transplant 2001; 7 Suppl:11S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/50\">",
"      Nichols WG, Erdman DD, Han A, et al. Prolonged outbreak of human parainfluenza virus 3 infection in a stem cell transplant outpatient department: insights from molecular epidemiologic analysis. Biol Blood Marrow Transplant 2004; 10:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/51\">",
"      Zambon M, Bull T, Sadler CJ, et al. Molecular epidemiology of two consecutive outbreaks of parainfluenza 3 in a bone marrow transplant unit. J Clin Microbiol 1998; 36:2289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/52\">",
"      Vilchez R, McCurry K, Dauber J, et al. Influenza and parainfluenza respiratory viral infection requiring admission in adult lung transplant recipients. Transplantation 2002; 73:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/53\">",
"      Kuo E, Bharat A, Goers T, et al. Respiratory viral infection in obliterative airway disease after orthotopic tracheal transplantation. Ann Thorac Surg 2006; 82:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/54\">",
"      Winter JB, Gouw AS, Groen M, et al. Respiratory viral infections aggravate airway damage caused by chronic rejection in rat lung allografts. Transplantation 1994; 57:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/55\">",
"      Billings JL, Hertz MI, Savik K, Wendt CH. Respiratory viruses and chronic rejection in lung transplant recipients. J Heart Lung Transplant 2002; 21:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/56\">",
"      Garbino J, Gerbase MW, Wunderli W, et al. Respiratory viruses and severe lower respiratory tract complications in hospitalized patients. Chest 2004; 125:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/57\">",
"      Erard V, Chien JW, Kim HW, et al. Airflow decline after myeloablative allogeneic hematopoietic cell transplantation: the role of community respiratory viruses. J Infect Dis 2006; 193:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/58\">",
"      Ferguson PE, Sorrell TC, Bradstock KF, et al. Parainfluenza Virus Type 3 Pneumonia in Bone Marrow Transplant Recipients: Multiple Small Nodules in High-Resolution Lung Computed Tomography Scans Provide a Radiological Clue to Diagnosis. Clin Infect Dis 2009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/59\">",
"      Sung RY, Chan PK, Choi KC, et al. Comparative study of nasopharyngeal aspirate and nasal swab specimens for diagnosis of acute viral respiratory infection. J Clin Microbiol 2008; 46:3073.",
"     </a>",
"    </li>",
"    <li>",
"     Leland, DS. Parainfluenza and Mumps Viruses. In: Manual of Clinical Microbiology, Murray, PR, Baron, EJ, Jorgensen, JH, et al (Eds), ASM Press, Washington, DC 2007. p. 1352.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/61\">",
"      Engler HD, Preuss J. Laboratory diagnosis of respiratory virus infections in 24 hours by utilizing shell vial cultures. J Clin Microbiol 1997; 35:2165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/62\">",
"      Kuypers J, Wright N, Ferrenberg J, et al. Comparison of real-time PCR assays with fluorescent-antibody assays for diagnosis of respiratory virus infections in children. J Clin Microbiol 2006; 44:2382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/63\">",
"      Mahony JB. Detection of respiratory viruses by molecular methods. Clin Microbiol Rev 2008; 21:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/64\">",
"      Fan J, Henrickson KJ. Rapid diagnosis of human parainfluenza virus type 1 infection by quantitative reverse transcription-PCR-enzyme hybridization assay. J Clin Microbiol 1996; 34:1914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/65\">",
"      Fan J, Henrickson KJ, Savatski LL. Rapid simultaneous diagnosis of infections with respiratory syncytial viruses A and B, influenza viruses A and B, and human parainfluenza virus types 1, 2, and 3 by multiplex quantitative reverse transcription-polymerase chain reaction-enzyme hybridization assay (Hexaplex). Clin Infect Dis 1998; 26:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/66\">",
"      Liolios L, Jenney A, Spelman D, et al. Comparison of a multiplex reverse transcription-PCR-enzyme hybridization assay with conventional viral culture and immunofluorescence techniques for the detection of seven viral respiratory pathogens. J Clin Microbiol 2001; 39:2779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/67\">",
"      Templeton KE, Scheltinga SA, Beersma MF, et al. Rapid and sensitive method using multiplex real-time PCR for diagnosis of infections by influenza a and influenza B viruses, respiratory syncytial virus, and parainfluenza viruses 1, 2, 3, and 4. J Clin Microbiol 2004; 42:1564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/68\">",
"      Li PQ, Yang ZF, Chen JX, et al. Simultaneous detection of different respiratory virus by a multiplex reverse transcription polymerase chain reaction combined with flow-through reverse dot blotting assay. Diagn Microbiol Infect Dis 2008; 62:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/69\">",
"      Pabbaraju K, Wong S, Tokaryk KL, et al. Comparison of the Luminex xTAG respiratory viral panel with xTAG respiratory viral panel fast for diagnosis of respiratory virus infections. J Clin Microbiol 2011; 49:1738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/70\">",
"      Pierce VM, Elkan M, Leet M, et al. Comparison of the Idaho Technology FilmArray system to real-time PCR for detection of respiratory pathogens in children. J Clin Microbiol 2012; 50:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/71\">",
"      Krunic N, Merante F, Yaghoubian S, et al. Advances in the diagnosis of respiratory tract infections: role of the Luminex xTAG respiratory viral panel. Ann N Y Acad Sci 2011; 1222:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/72\">",
"      Elizaga J, Olavarria E, Apperley J, et al. Parainfluenza virus 3 infection after stem cell transplant: relevance to outcome of rapid diagnosis and ribavirin treatment. Clin Infect Dis 2001; 32:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/73\">",
"      Chakrabarti S, Collingham KE, Holder K, et al. Parainfluenza virus type 3 infections in hematopoetic stem cell transplant recipients: response to ribavirin therapy. Clin Infect Dis 2000; 31:1516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/74\">",
"      Cobian L, Houston S, Greene J, Sinnott JT. Parainfluenza virus respiratory infection after heart transplantation: successful treatment with ribavirin. Clin Infect Dis 1995; 21:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/75\">",
"      Wright JJ, O'driscoll G. Treatment of parainfluenza virus 3 pneumonia in a cardiac transplant recipient with intravenous ribavirin and methylprednisolone. J Heart Lung Transplant 2005; 24:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/76\">",
"      Alymova IV, Portner A, Takimoto T, et al. The novel parainfluenza virus hemagglutinin-neuraminidase inhibitor BCX 2798 prevents lethal synergism between a paramyxovirus and Streptococcus pneumoniae. Antimicrob Agents Chemother 2005; 49:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/77\">",
"      Alymova IV, Taylor G, Takimoto T, et al. Efficacy of novel hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 against human parainfluenza viruses in vitro and in vivo. Antimicrob Agents Chemother 2004; 48:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/78\">",
"      Moscona A, Porotto M, Palmer S, et al. A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo. J Infect Dis 2010; 202:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/79\">",
"      Chen YB, Driscoll JP, McAfee SL, et al. Treatment of parainfluenza 3 infection with DAS181 in a patient after allogeneic stem cell transplantation. Clin Infect Dis 2011; 53:e77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/80\">",
"      Guzm&aacute;n-Suarez BB, Buckley MW, Gilmore ET, et al. Clinical potential of DAS181 for treatment of parainfluenza-3 infections in transplant recipients. Transpl Infect Dis 2012; 14:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/81\">",
"      Ottolini MG, Hemming VG, Piazza FM, et al. Topical immunoglobulin is an effective therapy for parainfluenza type 3 in a cotton rat model. J Infect Dis 1995; 172:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/82\">",
"      Bitko V, Musiyenko A, Shulyayeva O, Barik S. Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 2005; 11:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/617/abstract/83\">",
"      Siegel JD, Rhinehart E, Jackson M, et al. 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings. Am J Infect Control 2007; 35:S65.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7009 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-89ED0DCEDC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_38_617=[""].join("\n");
var outline_f0_38_617=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      VIROLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Structure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Serotypes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Seasonality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Serotype prevalence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Severe disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H663929612\">",
"      Outbreaks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Immunocompetent hosts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Immunocompromised hosts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Approach to diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Antigen detection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Polymerase chain reaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Serology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Vaccine development",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Infection control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7009\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7009|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?9/38/9830\" title=\"diagnostic image 1\">",
"      Parainfluenza pneumonia chest CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7009|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/49/31505\" title=\"figure 1\">",
"      Parainfluenza gene maps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/28/16834\" title=\"figure 2\">",
"      PIV seasonality",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15272?source=related_link\">",
"      Epidemiology of influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=related_link\">",
"      General principles of infection control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36808?source=related_link\">",
"      Parainfluenza viruses in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_38_618="Risk factors for gastric cancer";
var content_f0_38_618=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Risk factors for gastric cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/38/618/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/38/618/contributors\">",
"     Annie On On Chan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/38/618/contributors\">",
"     Benjamin C Y Wong, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/38/618/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/38/618/contributors\">",
"     Mark Feldman, MD, MACP, AGAF, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/38/618/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/38/618/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/38/618/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric cancer has significant geographical, ethnic, and socioeconomic differences in distribution. This topic review will discuss risk factors for gastric cancer. Epidemiologic aspects are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/35/4661?source=see_link\">",
"     \"Epidemiology of gastric cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are two main histologic variants of gastric adenocarcinoma. The most frequent is the \"intestinal type\", so called because of its morphologic similarity to adenocarcinomas arising in the intestinal tract. The less common diffuse type gastric cancers are characterized by a lack of intercellular adhesions, which leaves them unable to form glandular structures. In patients with inherited form of diffuse type gastric cancer, the absence of intercellular adhesions is caused by a germline mutation in the cell adhesion protein E-cadherin. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Hereditary diffuse gastric cancer'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRECURSOR LESIONS FOR INTESTINAL TYPE CANCERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sequence of molecular events that underlies intestinal type gastric cancer is incompletely understood. In comparison, much more is known about the molecular pathogenesis of diffuse type gastric cancers, which display a prominent molecular abnormality in the cell adhesion protein E-cadherin (CDH1). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/33/30234?source=see_link\">",
"     \"Molecular genetics of colorectal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/26/33194?source=see_link\">",
"     \"Pathology and molecular pathogenesis of gastric cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One model for the \"intestinal type\" of gastric cancer describes a progression from chronic gastritis to chronic atrophic gastritis, to intestinal metaplasia, dysplasia, and eventually to adenocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Longstanding chronic superficial gastritis caused by chronic H. pylori infection, pernicious anemia, or possibly a high salt diet leads eventually to chronic atrophic gastritis and intestinal metaplasia.",
"     </li>",
"     <li>",
"      Gastric atrophy is accompanied by a loss of parietal cell mass and therefore a reduction in acid production (hypochlorhydria or achlorhydria), a decrease in luminal ascorbic acid (vitamin C) levels, and a compensatory increase in serum gastrin, a potent inducer of gastric epithelial cell proliferation.",
"      <br/>",
"      <br/>",
"      Similarly, gastric resection results in hypo- or achlorhydria, secondary hypergastrinemia, and bile reflux, especially after a Billroth II anastomosis. The increase in gastric pH would permit colonization of bacteria capable of converting dietary nitrates to potent mutagenic N-nitroso compounds.",
"     </li>",
"     <li>",
"      Chronic inflammation results in epithelial cell damage with increased free radical generation, a further reduction in luminal ascorbic acid levels, and increased cell turnover.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Atrophic gastritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrophic gastritis is an autoimmune disorder that is characterized by progressive atrophy of the glandular epithelium with loss of parietal and chief cells. The loss of the normal exocrine glands of the gastric mucosa causes hypochlorhydria (decrease in hydrochloric acid) and a resultant increase in gastric pH. An abnormally high pH in the stomach permits microbial colonization, some of which possess nitrate reductase, allowing nitrosation that is genotoxic. In addition, there is a loss of endocrine cells, which normally secrete epidermal and transforming growth factors, thereby aiding the stomach in regenerating damaged tissue. Populations with a high prevalence of atrophic gastritis also have a high prevalence of gastric cancer, and vice versa [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Atrophic gastritis, and other conditions that cause gastric atrophy are associated with an increased risk of both cardia and non-cardia gastric adenocarcinomas (",
"    <a class=\"graphic graphic_figure graphicRef79793 \" href=\"UTD.htm?4/45/4817\">",
"     figure 1",
"    </a>",
"    ). The magnitude of the risk is variable in the literature, with estimates ranging from 3 to 18 times greater than an age-matched population. This subject is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24185?source=see_link&amp;anchor=H11#H11\">",
"     \"Metaplastic (chronic) atrophic gastritis\", section on 'Gastric adenocarcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Intestinal metaplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metaplasia is a potentially reversible change from one fully differentiated cell type to another, a process of adaptation to environmental stimuli. The most common form of metaplasia in the stomach is the intestinal type (",
"    <a class=\"graphic graphic_picture graphicRef64199 \" href=\"UTD.htm?17/24/17802\">",
"     picture 1",
"    </a>",
"    ). It occurs as a result of Helicobacter pylori infection, bile reflux, or can be induced experimentally by irradiation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Intestinal metaplasia is more frequent in countries with a higher incidence of gastric carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/6\">",
"     6",
"    </a>",
"    ], and, at least in experimental animal models, it precedes the development of gastric carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/7\">",
"     7",
"    </a>",
"    ]. An approach to patients with intestinal metaplasia is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24185?source=see_link\">",
"     \"Metaplastic (chronic) atrophic gastritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data from humans also provides support for the concept of intestinal metaplasia as a precursor lesion for intestinal type gastric cancer. A study from Japan found that the presence of intestinal metaplasia was the only criteria associated with the development of intestinal type gastric cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/8\">",
"     8",
"    </a>",
"    ]. In China, intestinal metaplasia was found in 33 percent of the population in a high prevalence area of gastric cancer; and dysplasia, common in the lesser curvature of the body and in the incisura, was found in 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Dysplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients diagnosed with high-grade dysplasia of the gastric mucosa either already have or soon develop gastric cancer. In gastrectomy specimens for gastric cancer, 20 to 40 percent of patients have associated dysplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/10\">",
"     10",
"    </a>",
"    ]. Rates of progression from dysplasia to gastric cancer have been estimated at 21, 33, and 57 percent of cases of mild, moderate, and severe dysplasia, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/10\">",
"     10",
"    </a>",
"    ]. In epidemiologic studies, intestinal metaplasia and dysplasia in the stomach are associated with a high cancer risk as illustrated by a study carried out in two provinces in China with high and low cancer risk [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/9\">",
"     9",
"    </a>",
"    ]. The prevalence of intestinal metaplasia and dysplasia was much higher in areas with high risk for gastric cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PRECURSOR LESIONS FOR DIFFUSE TYPE CANCERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to intestinal type gastric cancers, diffuse type gastric cancers have no clearly defined precancerous lesion. Diffuse type gastric cancer is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/26/33194?source=see_link\">",
"     \"Pathology and molecular pathogenesis of gastric cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ENVIRONMENTAL RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are geographic and ethnic differences in the incidence of gastric cancer around the world, as well as trends in each population over time. Emigrants from high-incidence to low-incidence countries often experience a decreased risk of developing gastric carcinoma. Such findings strongly suggest that environmental factors have an important role in the etiology of gastric cancer and that exposure to risk factors occurs early in life. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/35/4661?source=see_link\">",
"     \"Epidemiology of gastric cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Diet",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H367054345\">",
"    <span class=\"h3\">",
"     Salt and salt-preserved foods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Substantial evidence from ecological, case-control, and cohort studies strongly suggest that the risk of gastric cancer increases with a high intake of salt and various traditional salt-preserved foods such as salted fish, cured meat, and salted vegetables [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/11-16\">",
"     11-16",
"    </a>",
"    ]. In 2007, salt and",
"    <span class=\"nowrap\">",
"     salted/salty",
"    </span>",
"    foods were classified as probable risk factors for gastric cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A potential synergistic effect of salt and H. pylori has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/15\">",
"     15",
"    </a>",
"    ], though not in all studies [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/16\">",
"     16",
"    </a>",
"    ]. The role of salt and salted foods in the causal link between H. pylori and gastric cancer is discussed in more detail below. (See",
"    <a class=\"local\" href=\"#H21378716\">",
"     'Helicobacter pylori'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    High salt intake damages stomach mucosa and increases the susceptibility to carcinogenesis in rodents [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. The induced proliferative change may act to promote the effect of food-derived carcinogens.",
"   </p>",
"   <p>",
"    The declining incidence of gastric cancer worldwide over the last 50 years has been attributed, at least in part, to the spread of refrigeration [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/21\">",
"     21",
"    </a>",
"    ] , the use of which would inversely correlate with salting and other salt-based methods of preservation such as curing and smoking, and with the overall volume of salt in the diet. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/35/4661?source=see_link\">",
"     \"Epidemiology of gastric cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Nitroso compounds",
"    </span>",
"    &nbsp;&mdash;&nbsp;Humans are exposed to N-nitroso compounds (compounds containing an -NO group) from diet, tobacco smoke, and other environmental sources as well as from endogenous synthesis, which contributes to 40 to 75 percent of total exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/22\">",
"     22",
"    </a>",
"    ]. N-nitroso compounds are generated after consumption of nitrates, which are natural components of foods like vegetables and potatoes and are used as a food additive in some cheeses and cured meats. Dietary nitrates are absorbed in the stomach and secreted in saliva in a concentrated form where they are reduced to nitrites by oral bacteria. Nitrites can also react with nitrosatable compounds like amines, amides, and amino acids to form N-nitroso compounds.",
"   </p>",
"   <p>",
"    The evidence linking N-nitroso compounds to gastric cancer is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Elevated levels of gastric nitrite, particularly in a high pH environment, have been linked to advanced precancerous gastric lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The risk of gastric cancer associated with dietary intake of nitrites and nitrosodimethylamine (NDMA) and endogenous formation of nitroso compounds was investigated in the EPIC (European Prospective Investigation into Cancer and Nutrition) study [",
"      <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/24\">",
"       24",
"      </a>",
"      ]. While there was no association between intake of nitrites and NMDA and gastric cancer risk, endogenous production of N-nitroso compounds was significantly associated with non-cardia cancer risk (hazard ratio [HR] 1.42, 95% CI 1.14-1.78).",
"     </li>",
"     <li>",
"      Diets that are high in fried food, processed meat, and fish and alcohol (and low in vegetables, fruits, milk, and vitamin A) have been associated with an increased risk of gastric carcinoma in several epidemiologic studies [",
"      <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/14,25\">",
"       14,25",
"      </a>",
"      ]. A meta-analysis estimated that the relative risk of gastric cancer associated with consumption of 30 g of processed meat per day (about one-half an average serving) was 1.15 (95% CI 1.04-1.27) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/26\">",
"       26",
"      </a>",
"      ]. The risk of noncardia gastric cancer was particularly increased by red and processed meat consumption among H. pylori positive individuals in a large, prospective nutrition survey [",
"      <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H367054797\">",
"    <span class=\"h3\">",
"     Fruits, vegetables, and fiber",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consumption of fruits and vegetables, particularly fruit, is probably protective against gastric cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/11\">",
"     11",
"    </a>",
"    ]. Case-control studies from Europe, Asia, and North America have consistently found intake of fruits and vegetables to be protective against gastric cancer, reducing the risk by approximately 40 percent for fruits, and 30 percent for vegetables for the highest versus lowest categories of intake, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/27-30\">",
"     27-30",
"    </a>",
"    ]. Diets low in citrus fruit show the strongest association with gastric carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cohort studies have been less consistent; a meta-analysis found a weaker overall association in the reduction of gastric cancer risk from 18 percent for a high intake of fruits to 12 percent for a high intake of vegetables [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/32\">",
"     32",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    The protection afforded by vegetables and fruits is most likely related to their vitamin C content, which is thought to reduce the formation of carcinogenic N-nitroso compounds inside the stomach. Cooked vegetables do not show the same protective effect as uncooked vegetables [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cereal fiber has been confirmed in a prospective study to have a strong protective role of diffuse type of gastric cancer, but not intestinal type [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Folate",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of epidemiology studies found an inconsistent association between dietary folate and the risk of gastric cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excess body weight is associated with an increased risk of gastric cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. In a meta-analysis of cohort studies identifying 9492 gastric cancer cases, excess body weight (defined as a BMI &ge;25",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    was associated with an increased risk of gastric cancer (OR=1.22, 95% CI 1.06-1.41) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/36\">",
"     36",
"    </a>",
"    ]. The strength of the association increased with increasing BMI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have examined the relationship between tobacco smoking and gastric cancer. A meta-analysis of 42 studies estimated that the risk was increased by approximately 1.53-fold and was higher in men [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/38\">",
"     38",
"    </a>",
"    ]. A prospective study from Europe (EPIC) found a similar magnitude of risk, which diminished after 10 years of smoking cessation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/39\">",
"     39",
"    </a>",
"    ]. Approximately 18 percent of gastric cancer cases were attributed to smoking.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21378716\">",
"    <span class=\"h2\">",
"     Helicobacter pylori",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Health Organization's International Agency for Research on Cancer classified Helicobacter pylori (H. pylori) as a Group 1 or definite carcinogen [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/40\">",
"     40",
"    </a>",
"    ]. As noted above, intestinal type gastric carcinoma is believed to evolve as a progression from atrophy to metaplasia, dysplasia and then carcinoma. The most common cause of gastritis is H. pylori (",
"    <a class=\"graphic graphic_picture graphicRef51050 \" href=\"UTD.htm?10/19/10547\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Four sources of evidence support an association between H. pylori infection and gastric cancer: epidemiologic studies comparing prevalence rates of gastric cancer and H. pylori infection, cross-sectional studies evaluating H. pylori infection in patients with gastric cancer, prospective studies associating H. pylori infection with gastric cancer, and clinical trials demonstrating a significantly reduced incidence of gastric cancer after eradication of H. pylori. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2634?source=see_link\">",
"     \"Association between Helicobacter pylori infection and gastrointestinal malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is thought that Helicobacter pylori infection triggers inflammation at the corpus mucosa that results in atrophy and intestinal metaplasia. H. pylori infection has been associated with an approximate 6-fold increase in the risk with adenocarcinomas distal to the cardia, including both the intestinal and diffuse types. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2634?source=see_link\">",
"     \"Association between Helicobacter pylori infection and gastrointestinal malignancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/26/33194?source=see_link\">",
"     \"Pathology and molecular pathogenesis of gastric cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A paradox in H. pylori infection is that divergent clinical outcomes occur: some patients develop duodenal ulcer or gastric cancer, while the majority have no significant clinical symptoms. Bacterial virulence factors alone have not adequately explained why the ulcer or the gastric cancer phenotype develops. Ongoing studies are helping to elucidate the basis for these varying outcomes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2634?source=see_link\">",
"     \"Association between Helicobacter pylori infection and gastrointestinal malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21378723\">",
"    <span class=\"h3\">",
"     Influence of salt and intake of salted foods",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, there is a link between intake of salt and highly salted foods and gastric cancer risk; high salt intake damages stomach mucosa and increases the susceptibility to carcinogenesis.",
"   </p>",
"   <p>",
"    The consumption of salted food appears to increase the possibility of persistent infection with H. pylori infection [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. In addition, a synergistic interaction between H. pylori infection and salted food intake to increase the risk of gastric cancer has also been reported in some [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/15,43,44\">",
"     15,43,44",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/16\">",
"     16",
"    </a>",
"    ], case-control studies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/16/43271?source=see_link\">",
"     \"Bacteriology and epidemiology of Helicobacter pylori infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21378730\">",
"    <span class=\"h3\">",
"     Possible protective effect of NSAIDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regular use of NSAIDs has been inversely associated with the risk of distal gastric adenocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. There appears to be an interaction between NSAID use and H. pylori infection. A retrospective study looked at 52,161 patients who had been hospitalized with peptic ulcer disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/45\">",
"     45",
"    </a>",
"    ]. On multivariate analysis, regular NSAID use was an independent protective factor against the development of gastric cancer (hazard ratio [HR] 0.79 for each year of NSAID use), and the protective effect was most pronounced in patients with a history of H. pylori infection (HR 0.52 for each incremental year).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21379094\">",
"    <span class=\"h2\">",
"     Epstein-Barr virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection with Epstein-Barr virus (EBV) is associated with a number of malignancies, especially nasopharyngeal carcinoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26184?source=see_link&amp;anchor=H8#H8\">",
"     \"Epidemiology, etiology, and diagnosis of nasopharyngeal carcinoma\", section on 'Epstein-Barr virus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A possible role in gastric cancer was initially suggested in a study from Korea in which evidence of EBV was found in the tumor cells of 12 of 89 (13 percent) gastric carcinoma patients compared to none of 27 controls with a benign ulcer or any of the benign tissues from the cases [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/47\">",
"     47",
"    </a>",
"    ]. Some of the tumor cells had a histologic appearance similar to nasopharyngeal carcinoma.",
"   </p>",
"   <p>",
"    Since then, it has been estimated that between 5 and 10 percent of gastric cancers worldwide are associated with EBV [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. EBV-associated gastric cancers are characterized by DNA methylation of the promoter region of various cancer-associated genes, which silences the expression of these genes [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/50-55\">",
"     50-55",
"    </a>",
"    ]. How this leads to gastric cancer is unclear, but silencing of expression of certain genes may modulate the latent-lytic switch of EBV infection, allowing the virus to escape immune detection and remain dormant within the host cells [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    EBV-associated gastric cancers have distinct clinicopathologic characteristics, including male predominance, preferential location in the gastric cardia or postsurgical gastric stump, lymphocytic infiltration, a lower frequency of lymph node metastases, perhaps a more favorable prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/50,52,57-60\">",
"     50,52,57-60",
"    </a>",
"    ], and a diffuse type of histology in most [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/50,52,53,60,61\">",
"     50,52,53,60,61",
"    </a>",
"    ] but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/56-58\">",
"     56-58",
"    </a>",
"    ] series. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/26/33194?source=see_link\">",
"     \"Pathology and molecular pathogenesis of gastric cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Alcohol",
"    </span>",
"    &nbsp;&mdash;&nbsp;A consistent association between alcohol consumption and the risk of gastric cancer has not been demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. A study from Europe suggested that daily intake of wine may be protective [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Socioeconomic status",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of distal gastric cancer is increased by approximately twofold in populations with low socioeconomic status [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/64-67\">",
"     64-67",
"    </a>",
"    ]. By contrast, proximal gastric cancers have been associated with higher socioeconomic class [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Gastric surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is an increased risk of gastric cancer after gastric surgery, with the risk being greatest 15 to 20 years after surgery and then increasing with time [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. Two meta-analyses estimate the relative risk to be in the range of 1.5 to 3.0, depending on the type of surgery, duration of follow-up, and geographic location [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. The Billroth II procedure (gastrojejunostomy) carries a higher risk than the Billroth I (gastroduodenostomy). Although the exact cause of the increased risk is unknown, it is thought to be due to regurgitation of alkaline bile and pancreatic juice (which is greater after a Billroth II compared with a Billroth I).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Reproductive hormones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric cancer incidence rates are consistently lower in women than men in both high and low-risk regions worldwide. There are data that support the hypothesis that reproductive hormones may have a protective role in gastric cancer risk in women [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. One study found that there were associations between age of menopause (HR 0.80 per five year increase in menopausal age, 95% CI 0.66-0.97), years of fertility (participants with less than 30 years of fertility were at increased risk compared with those with 30 to 36 years of fertility, HR 1.90, 95% CI 1.25-2.90), years since menopause (HR 1.26 per each five years, 95% CI 1.03-1.53), and intrauterine device use (HR for users 1.61, 95% CI 1.08-2.39) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     HOST-RELATED FACTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Blood group",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of genetic factors was first suggested by the study of blood groups and determinants of chronic gastritis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/75\">",
"     75",
"    </a>",
"    ]. Individuals of blood group A have been known for decades to show an approximately 20 percent excess of gastric cancer than those of group O, B, or AB [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/76-78\">",
"     76-78",
"    </a>",
"    ]. They also show a similar increase in the rate of pernicious anaemia. Some data suggest that group A may be particularly associated with the diffuse type of gastric cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/75\">",
"     75",
"    </a>",
"    ]. It is possible that the observed associations are not due to the blood group antigens themselves, but to the effects of genes closely associated with them.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Familial predisposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;A genetic predisposition to gastric cancer has been repeatedly confirmed [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/75,79-81\">",
"     75,79-81",
"    </a>",
"    ]. In some families, the underlying genetic basis for the predisposition is not understood, while in others, certain risk factors have been identified.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some of the observed familial risk may be due to clustering of H. pylori infection within families [",
"      <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/82\">",
"       82",
"      </a>",
"      ]. However, a case-control study found that a family history increased the risk of gastric cancer independently of H. pylori infection [",
"      <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/83\">",
"       83",
"      </a>",
"      ]. Another case-control study found that a positive history of gastric cancer in one or more first-degree relatives was associated with an increased risk of gastric cancer in women (OR = 5.1) but not in men after controlling for H. pylori infection and other confounding variables [",
"      <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/84\">",
"       84",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A genetic predisposition for chronic atrophic gastritis, a precursor of gastric carcinoma, has been described and may account for at least some cases of familial gastric cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/85\">",
"       85",
"      </a>",
"      ]. The genetic segregation analysis showed Mendelian transmission of a recessive autosomal gene with penetrance dependent on age and the status of chronic atrophic gastritis in the mother. Significantly more patients were affected whose mothers were also affected (48 versus 7 percent).",
"     </li>",
"     <li>",
"      Gastric cancer has been described in association with certain cancer syndromes including hereditary nonpolyposis colorectal cancer, familial adenomatous polyposis, Li-Fraumeni syndrome, hereditary diffuse gastric cancer, and Peutz Jeghers syndrome, but these are all fairly rare. (See appropriate topic reviews).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Hereditary diffuse gastric cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary diffuse gastric cancer (HDGC) is an inherited form of diffuse type gastric cancer, a highly invasive tumor that is characterized by late presentation and a poor prognosis.",
"   </p>",
"   <p>",
"    Germline truncating CDH1 mutations have been identified in approximately 30 to 50 percent of affected kindreds who meet the clinical criteria for HDGC as described by the International Gastric Cancer Linkage Consortium (IGCLC, see below). These mutations are not concentrated in a single hotspot, but rather evenly distributed along the gene in several different exons. The trigger and molecular mechanism by which the second allele of E-cadherin is inactivated appears to be diverse, and includes promoter hypermethylation, mutation, and loss of heterozygosity. The end result is loss of expression of the cell adhesion molecule E-cadherin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2296?source=see_link\">",
"     \"Hereditary diffuse gastric cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/26/33194?source=see_link&amp;anchor=H15#H15\">",
"     \"Pathology and molecular pathogenesis of gastric cancer\", section on 'Molecular pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HDGC is inherited as an autosomal dominant trait with high penetrance. The lifetime cumulative risk for advanced gastric cancer is between 40 and 67 percent in men, and 60 to 83 percent in women. Affected patients generally develop gastric cancer at an early age (average 38). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2296?source=see_link&amp;anchor=H3#H3\">",
"     \"Hereditary diffuse gastric cancer\", section on 'Risk of cancer in mutation carriers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of gastric cancer in asymptomatic carriers of germline truncating mutations in E-cadherin who belong to families with highly penetrant hereditary diffuse gastric cancer is sufficiently high to warrant prophylactic gastrectomy, although the age at which the procedure should be done is unclear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/34/3625?source=see_link&amp;anchor=H6#H6\">",
"     \"Prophylactic total gastrectomy for hereditary diffuse gastric cancer\", section on 'Age and fertility considerations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women in these affected families are also at high risk of developing lobular breast cancer. As a result, women from these families should be counseled and strongly encouraged to undergo breast cancer screening. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17418?source=see_link\">",
"     \"Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Genetic polymorphisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain polymorphisms have been associated with gastric cancer:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The human interleukin 1 beta (IL-1B) gene is the most important candidate gene in the host that could affect the clinical outcome of H. pylori infection because it is upregulated by infection, is profoundly proinflammatory, and is the most powerful acid inhibitor known. Polymorphisms in IL-1B gene (carriers of IL-1B-511*T) and in the IL-1 receptor antagonist gene",
"      <span class=\"nowrap\">",
"       (IL-1RN*2/*2)",
"      </span>",
"      have been associated with an increased risk of gastric cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/86\">",
"       86",
"      </a>",
"      ]. Another study showed that polymorphisms (IL-1B-511*T carriers",
"      <span class=\"nowrap\">",
"       {IL-1B-511*T/*T",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       IL-1B-511*T/*C})",
"      </span>",
"      and H. pylori virulence factors (vacAs1-, vacAm1-, and cagA-positive) were additive in increasing the risk of gastric cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/87\">",
"       87",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      IFNGR1 gene encodes chain 1 of the interferon-gamma (IFN-gamma) receptor. Sequencing of IFNGR1 revealed that the -56C--&gt;T, H318P, and L450P variants were associated with high H. pylori antibody concentrations [",
"      <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/88\">",
"       88",
"      </a>",
"      ]. The variants were more prevalent in Africans than in whites. These findings indicate that IFN-gamma signaling has an essential role in human H. pylori infection, and it might in part explain why H. pylori infection is highly prevalent in Africa but is relatively less pathogenic [",
"      <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/88\">",
"       88",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Polymorphisms of methylenetetrahydrofolate (MTHF) reductase have been associated with gastric cancer, mainly in East Asians [",
"      <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/89\">",
"       89",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Gastric polyps",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric polyps are typically found incidentally when upper gastrointestinal endoscopy is performed for an unrelated indication; only rarely do they cause symptoms or other clinical signs. Nevertheless, their discovery can be important since many polyps have malignant potential. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/19/2361?source=see_link\">",
"     \"Gastric polyps\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Hypertrophic gastropathy and immunodeficiency syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertrophic gastropathy (including M&eacute;n&eacute;trier's disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/72\">",
"     72",
"    </a>",
"    ] and various immunodeficiency syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/90,91\">",
"     90,91",
"    </a>",
"    ] have been linked with gastric cancer. However, the strength of these associations remains undefined. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/58/2984?source=see_link\">",
"     \"Large gastric folds: Hyperplastic and nonhyperplastic gastropathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Gastric ulcer",
"    </span>",
"    &nbsp;&mdash;&nbsp;An association between benign gastric ulcers and gastric cancers probably reflects common risk factors (ie, mainly H. pylori infection) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/92-95\">",
"     92-95",
"    </a>",
"    ]. The largest cohort study followed (for an average of nine years) almost 60,000 Swedish patients who had been hospitalized for gastric or duodenal ulcer [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/96\">",
"     96",
"    </a>",
"    ]. The risk of gastric cancer was increased among patients with benign gastric ulcers (incidence ratio 1.8), unchanged among patients with prepyloric ulcers, and decreased among those with benign duodenal ulcers (incidence ratio 0.6).",
"   </p>",
"   <p>",
"    In a study from Japan, 1120 patients with peptic ulcer disease who had H. pylori eradication therapy were followed up for a mean of 3.4 years [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/97\">",
"     97",
"    </a>",
"    ]. Gastric cancer developed only in patients with a gastric ulcer but not patients with duodenal ulcers. Patients who developed gastric cancer were significantly more likely to have persistent H. pylori infection (hazard ratio 3.4). A follow-up study from the same group showed that, in patients with peptic ulcer diseases, the risk of gastric cancer was significantly increased with persistent H. pylori infection, a higher grade of baseline gastric mucosal atrophy, and older age [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Pernicious anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pernicious anemia, a sequela of autoimmune chronic atrophic gastritis directed against hydrogen-potassium ATPase in the gastric parietal cells, is associated with an increased risk of intestinal-type gastric cancer. A two- to sixfold excess risk has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/99-102\">",
"     99-102",
"    </a>",
"    ] but, as with other predisposing conditions, the actual degree of risk varies with the duration of disease and geographic location. Pernicious anemia is also associated with an increased risk of gastric carcinoid tumors, presumably due to prolonged achlorhydria resulting from parietal cell loss, compensatory hypergastrinemia, and argyrophilic cell hyperplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/103\">",
"     103",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11786?source=see_link&amp;anchor=H6#H6\">",
"     \"Etiology and clinical manifestations of vitamin B12 and folate deficiency\", section on 'Pernicious anemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24185?source=see_link&amp;anchor=H10#H10\">",
"     \"Metaplastic (chronic) atrophic gastritis\", section on 'Carcinoid tumors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24185?source=see_link&amp;anchor=H11#H11\">",
"     \"Metaplastic (chronic) atrophic gastritis\", section on 'Gastric adenocarcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On the other hand, \"iatrogenic\" achlorhydria induced by long-term use of histamine-2-receptor antagonists or proton pump inhibitors has not been associated with an increased risk of either gastric adenocarcinomas or carcinoid tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/104-107\">",
"     104-107",
"    </a>",
"    ]. An association between maintenance therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    and the development of atrophic gastritis in individuals with H. pylori infection has been suggested but the data are inconclusive. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25034?source=see_link&amp;anchor=H59974972#H59974972\">",
"     \"Overview and comparison of the proton pump inhibitors for the treatment of acid-related disorders\", section on 'Atrophic gastritis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the benefit of screening or surveillance endoscopy in patients with pernicious anemia has not been established, a guideline issued by the American Society for Gastrointestinal Endoscopy recommends that [",
"    <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/108\">",
"     108",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A single endoscopy should be performed to identify prevalent lesions (carcinoid tumors and gastric cancer).",
"     </li>",
"     <li>",
"      There are insufficient data to support subsequent surveillance endoscopy in patients without these findings.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite these recommendations, the cost-effectiveness of initial screening endoscopy in patients with pernicious anemia is uncertain. This subject is addressed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/0/5130?source=see_link&amp;anchor=H28#H28\">",
"     \"Diagnosis and treatment of vitamin B12 and folate deficiency\", section on 'Monitoring for malignancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     INTERPLAY BETWEEN HOST AND ENVIRONMENTAL FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several observations have described interplay between host and environmental factors.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As noted above, higher salt intake correlates with a higher prevalence of persistent H. pylori infection, and a higher risk of gastric cancer in those infected with H. pylori. A possible explanation is that mucosal damage caused by high salt intake facilitates H. pylori infection. The resultant hypochlorhydria and bacterial overgrowth, with the subsequent conversion of nitrites to the mutagenic N-nitrosamines, may then lead to metaplasia, dysplasia, and cancer. (See",
"      <a class=\"local\" href=\"#H21378723\">",
"       'Influence of salt and intake of salted foods'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gastric juice of H. pylori-positive individuals had lower concentration of vitamin C than H. pylori-negative individuals, but the concentration returned to normal when H. pylori was eradicated [",
"      <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/109\">",
"       109",
"      </a>",
"      ]. As a result, vitamin C may have an important role in preventing the damage caused by H. pylori through its antioxidant effect [",
"      <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/109\">",
"       109",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"       Beta-carotene",
"      </a>",
"      and ascorbic acid are believed to interfere with the progression to cancer through their anti-nitrosation and antioxidant effects, and thus act as protective factors [",
"      <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/110\">",
"       110",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A model of gastric carcinogenesis recognizes the interplay between exogenous risk factors (such as H. pylori or nitroso compounds), endogenous protective factors (such as the ability to repair DNA damage) and exogenous protective factors (such as antioxidants). H. pylori infection in early life leads to chronic inflammation. The resulting cellular proliferation increases the likelihood of mitotic error. Dietary mutagens may also increase the risk of mutation while dietary antioxidants act as protective factors. Because some DNA damage can be self-corrected, H pylori-related mutations only rarely lead to malignant transformation. Thus, longer duration of infection, especially infection acquired during childhood and continuing until old age, increases the risk of significant DNA damage with subsequent malignant transformation [",
"      <a class=\"abstract\" href=\"UTD.htm?0/38/618/abstract/110\">",
"       110",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      H. pylori genotype and host genetic polymorphisms have a role in determining the clinical consequences of H. pylori infection and hence the risk of developing gastric cancer. It has been suggested that combined",
"      <span class=\"nowrap\">",
"       bacterial/host",
"      </span>",
"      genotyping may provide an important tool in defining disease risk and targeting H. pylori eradication to high-risk individuals.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7442988\">",
"    <span class=\"h1\">",
"     SCREENING GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approaches to screening patients for gastric cancer are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/52/6983?source=see_link\">",
"     \"Screening and prevention of gastric cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gastric ulcers, adenomatous polyps, and intestinal metaplasia have been associated with an increased risk of gastric cancer. (See above).",
"     </li>",
"     <li>",
"      Gastric cancer developing in patients considered to be at average risk involves an interplay of bacterial, host, and environmental facts. Dietary (nitroso compounds, high salt diet with low vegetables) and lifestyle factors (smoking and alcohol consumption) probably account for one-third to one-half of all gastric cancers. H. pylori infection, especially certain genotypes (vacAs1-, vacAm1-, and cagA-positive), remains an important risk factor. The risk is increased further in hosts who possess specific types of cytokine polymorphisms",
"      <span class=\"nowrap\">",
"       (IL-1B-511*T/*T",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       IL-1B-511*T/*C).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/1\">",
"      Correa P. The gastric precancerous process. Cancer Surv 1983; 2:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/2\">",
"      Correa P. A human model of gastric carcinogenesis. Cancer Res 1988; 48:3554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/3\">",
"      Genta RM. Acid suppression and gastric atrophy: sifting fact from fiction. Gut 1998; 43 Suppl 1:S35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/4\">",
"      Sobala GM, O'Connor HJ, Dewar EP, et al. Bile reflux and intestinal metaplasia in gastric mucosa. J Clin Pathol 1993; 46:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/5\">",
"      Watanabe H. Experimentally induced intestinal metaplasia in Wistar rats by X-ray irradiation. Gastroenterology 1978; 75:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/6\">",
"      Correa P, Cuello C, Duque E. Carcinoma and intestinal metaplasia of the stomach in Colombian migrants. J Natl Cancer Inst 1970; 44:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/7\">",
"      Sasajima K, Kawachi T, Matsukura N, et al. Intestinal metaplasia and adenocarcinoma induced in the stomach of rats by N-propyl-N'-nitro-N-nitrosoguanidine. J Cancer Res Clin Oncol 1979; 94:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/8\">",
"      Shimoyama T, Fukuda S, Tanaka M, et al. Evaluation of the applicability of the gastric carcinoma risk index for intestinal type cancer in Japanese patients infected with Helicobacter pylori. Virchows Arch 2000; 436:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/9\">",
"      You WC, Blot WJ, Li JY, et al. Precancerous gastric lesions in a population at high risk of stomach cancer. Cancer Res 1993; 53:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/10\">",
"      Rugge M, Farinati F, Baffa R, et al. Gastric epithelial dysplasia in the natural history of gastric cancer: a multicenter prospective follow-up study. Interdisciplinary Group on Gastric Epithelial Dysplasia. Gastroenterology 1994; 107:1288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/11\">",
"      Tsugane S, Sasazuki S. Diet and the risk of gastric cancer: review of epidemiological evidence. Gastric Cancer 2007; 10:75.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Diet, nutrition, and the prevention of chronic diseases. WHOP technical report series 916. Geneva;  World Health Organization; 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/13\">",
"      Joossens JV, Hill MJ, Elliott P, et al. Dietary salt, nitrate and stomach cancer mortality in 24 countries. European Cancer Prevention (ECP) and the INTERSALT Cooperative Research Group. Int J Epidemiol 1996; 25:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/14\">",
"      Kono S, Hirohata T. Nutrition and stomach cancer. Cancer Causes Control 1996; 7:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/15\">",
"      Shikata K, Kiyohara Y, Kubo M, et al. A prospective study of dietary salt intake and gastric cancer incidence in a defined Japanese population: the Hisayama study. Int J Cancer 2006; 119:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/16\">",
"      Peleteiro B, Lopes C, Figueiredo C, Lunet N. Salt intake and gastric cancer risk according to Helicobacter pylori infection, smoking, tumour site and histological type. Br J Cancer 2011; 104:198.",
"     </a>",
"    </li>",
"    <li>",
"     World Cancer Research Fund/American Institute for Cancer Research (2007). Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective. World Cancer Research Fund/American Institute for Cancer Research: Washington DC.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/18\">",
"      Tatematsu M, Takahashi M, Fukushima S, et al. Effects in rats of sodium chloride on experimental gastric cancers induced by N-methyl-N-nitro-N-nitrosoguanidine or 4-nitroquinoline-1-oxide. J Natl Cancer Inst 1975; 55:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/19\">",
"      Takahashi M, Kokubo T, Furukawa F, et al. Effects of sodium chloride, saccharin, phenobarbital and aspirin on gastric carcinogenesis in rats after initiation with N-methyl-N'-nitro-N-nitrosoguanidine. Gann 1984; 75:494.",
"     </a>",
"    </li>",
"    <li>",
"     Hanawa K, Yamada S, Suzuki H, et al. Effects of sodium chloride on gastric cancer induction by N-methyl-N-Nitro-N-nitrogoguanidine (MNNG) in rats. Proceedings of the Thirty-ninth Annual Meeting of the Japanese Cancer Association, Tokyo: Japanese Cancer Association, 1980. p.49.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/21\">",
"      Park B, Shin A, Park SK, et al. Ecological study for refrigerator use, salt, vegetable, and fruit intakes, and gastric cancer. Cancer Causes Control 2011; 22:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/22\">",
"      Tricker AR. N-nitroso compounds and man: sources of exposure, endogenous formation and occurrence in body fluids. Eur J Cancer Prev 1997; 6:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/23\">",
"      You WC, Zhang L, Yang CS, et al. Nitrite, N-nitroso compounds, and other analytes in physiological fluids in relation to precancerous gastric lesions. Cancer Epidemiol Biomarkers Prev 1996; 5:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/24\">",
"      Jakszyn P, Bingham S, Pera G, et al. Endogenous versus exogenous exposure to N-nitroso compounds and gastric cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST) study. Carcinogenesis 2006; 27:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/25\">",
"      Gonz&aacute;lez CA, Jakszyn P, Pera G, et al. Meat intake and risk of stomach and esophageal adenocarcinoma within the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst 2006; 98:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/26\">",
"      Larsson SC, Orsini N, Wolk A. Processed meat consumption and stomach cancer risk: a meta-analysis. J Natl Cancer Inst 2006; 98:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/27\">",
"      Lunet N, Valbuena C, Vieira AL, et al. Fruit and vegetable consumption and gastric cancer by location and histological type: case-control and meta-analysis. Eur J Cancer Prev 2007; 16:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/28\">",
"      Liu C, Russell RM. Nutrition and gastric cancer risk: an update. Nutr Rev 2008; 66:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/29\">",
"      Riboli E, Norat T. Epidemiologic evidence of the protective effect of fruit and vegetables on cancer risk. Am J Clin Nutr 2003; 78:559S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/30\">",
"      Larsson SC, Bergkvist L, Wolk A. Fruit and vegetable consumption and incidence of gastric cancer: a prospective study. Cancer Epidemiol Biomarkers Prev 2006; 15:1998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/31\">",
"      La Vecchia C, Negri E, Decarli A, et al. A case-control study of diet and gastric cancer in northern Italy. Int J Cancer 1987; 40:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/32\">",
"      Lunet N, Lacerda-Vieira A, Barros H. Fruit and vegetables consumption and gastric cancer: a systematic review and meta-analysis of cohort studies. Nutr Cancer 2005; 53:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/33\">",
"      Buiatti E, Palli D, Decarli A, et al. A case-control study of gastric cancer and diet in Italy. Int J Cancer 1989; 44:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/34\">",
"      M A M, Pera G, Agudo A, et al. Cereal fiber intake may reduce risk of gastric adenocarcinomas: the EPIC-EURGAST study. Int J Cancer 2007; 121:1618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/35\">",
"      Larsson SC, Giovannucci E, Wolk A. Folate intake, MTHFR polymorphisms, and risk of esophageal, gastric, and pancreatic cancer: a meta-analysis. Gastroenterology 2006; 131:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/36\">",
"      Yang P, Zhou Y, Chen B, et al. Overweight, obesity and gastric cancer risk: results from a meta-analysis of cohort studies. Eur J Cancer 2009; 45:2867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/37\">",
"      Turati F, Tramacere I, La Vecchia C, Negri E. A meta-analysis of body mass index and esophageal and gastric cardia adenocarcinoma. Ann Oncol 2013; 24:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/38\">",
"      Ladeiras-Lopes R, Pereira AK, Nogueira A, et al. Smoking and gastric cancer: systematic review and meta-analysis of cohort studies. Cancer Causes Control 2008; 19:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/39\">",
"      Gonz&aacute;lez CA, Pera G, Agudo A, et al. Smoking and the risk of gastric cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). Int J Cancer 2003; 107:629.",
"     </a>",
"    </li>",
"    <li>",
"     IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, Schistosomes, Liver Flukes and Helicobacter pylori. Vol 61 of IARC monographs on the evaluation of carcinogenic risks to humans. International Agency for Research on Cancer, Lyon, 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/41\">",
"      Tsugane S, Tei Y, Takahashi T, et al. Salty food intake and risk of Helicobacter pylori infection. Jpn J Cancer Res 1994; 85:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/42\">",
"      Fox JG, Dangler CA, Taylor NS, et al. High-salt diet induces gastric epithelial hyperplasia and parietal cell loss, and enhances Helicobacter pylori colonization in C57BL/6 mice. Cancer Res 1999; 59:4823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/43\">",
"      Lee SA, Kang D, Shim KN, et al. Effect of diet and Helicobacter pylori infection to the risk of early gastric cancer. J Epidemiol 2003; 13:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/44\">",
"      Machida-Montani A, Sasazuki S, Inoue M, et al. Association of Helicobacter pylori infection and environmental factors in non-cardia gastric cancer in Japan. Gastric Cancer 2004; 7:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/45\">",
"      Wu CY, Wu MS, Kuo KN, et al. Effective reduction of gastric cancer risk with regular use of nonsteroidal anti-inflammatory drugs in Helicobacter pylori-infected patients. J Clin Oncol 2010; 28:2952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/46\">",
"      Epplein M, Nomura AM, Wilkens LR, et al. Nonsteroidal antiinflammatory drugs and risk of gastric adenocarcinoma: the multiethnic cohort study. Am J Epidemiol 2009; 170:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/47\">",
"      Shin WS, Kang MW, Kang JH, et al. Epstein-Barr virus-associated gastric adenocarcinomas among Koreans. Am J Clin Pathol 1996; 105:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/48\">",
"      Takada K. Epstein-Barr virus and gastric carcinoma. Mol Pathol 2000; 53:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/49\">",
"      Boysen T, Mohammadi M, Melbye M, et al. EBV-associated gastric carcinoma in high- and low-incidence areas for nasopharyngeal carcinoma. Br J Cancer 2009; 101:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/50\">",
"      Chang MS, Uozaki H, Chong JM, et al. CpG island methylation status in gastric carcinoma with and without infection of Epstein-Barr virus. Clin Cancer Res 2006; 12:2995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/51\">",
"      Sakuma K, Chong JM, Sudo M, et al. High-density methylation of p14ARF and p16INK4A in Epstein-Barr virus-associated gastric carcinoma. Int J Cancer 2004; 112:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/52\">",
"      Kusano M, Toyota M, Suzuki H, et al. Genetic, epigenetic, and clinicopathologic features of gastric carcinomas with the CpG island methylator phenotype and an association with Epstein-Barr virus. Cancer 2006; 106:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/53\">",
"      Kaneda A, Kaminishi M, Yanagihara K, et al. Identification of silencing of nine genes in human gastric cancers. Cancer Res 2002; 62:6645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/54\">",
"      Etoh T, Kanai Y, Ushijima S, et al. Increased DNA methyltransferase 1 (DNMT1) protein expression correlates significantly with poorer tumor differentiation and frequent DNA hypermethylation of multiple CpG islands in gastric cancers. Am J Pathol 2004; 164:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/55\">",
"      Fukayama M. Epstein-Barr virus and gastric carcinoma. Pathol Int 2010; 60:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/56\">",
"      Zhao J, Jin H, Cheung KF, et al. Zinc finger E-box binding factor 1 plays a central role in regulating Epstein-Barr virus (EBV) latent-lytic switch and acts as a therapeutic target in EBV-associated gastric cancer. Cancer 2012; 118:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/57\">",
"      Murphy G, Pfeiffer R, Camargo MC, Rabkin CS. Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location. Gastroenterology 2009; 137:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/58\">",
"      van Beek J, zur Hausen A, Klein Kranenbarg E, et al. EBV-positive gastric adenocarcinomas: a distinct clinicopathologic entity with a low frequency of lymph node involvement. J Clin Oncol 2004; 22:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/59\">",
"      Wu MS, Shun CT, Wu CC, et al. Epstein-Barr virus-associated gastric carcinomas: relation to H. pylori infection and genetic alterations. Gastroenterology 2000; 118:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/60\">",
"      Lee JH, Kim SH, Han SH, et al. Clinicopathological and molecular characteristics of Epstein-Barr virus-associated gastric carcinoma: a meta-analysis. J Gastroenterol Hepatol 2009; 24:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/61\">",
"      Fukayama M, Chong JM, Uozaki H. Pathology and molecular pathology of Epstein-Barr virus-associated gastric carcinoma. Curr Top Microbiol Immunol 2001; 258:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/62\">",
"      Barstad B, S&oslash;rensen TI, Tj&oslash;nneland A, et al. Intake of wine, beer and spirits and risk of gastric cancer. Eur J Cancer Prev 2005; 14:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/63\">",
"      Tramacere I, Negri E, Pelucchi C, et al. A meta-analysis on alcohol drinking and gastric cancer risk. Ann Oncol 2012; 23:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/64\">",
"      HAENSZEL W. Variation in incidence of and mortality from stomach cancer, with particular reference to the United States. J Natl Cancer Inst 1958; 21:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/65\">",
"      WYNDER EL, KMET J, DUNGAL N, SEGI M. AN EPIDEMIOLOGICAL INVESTIGATION OF GASTRIC CANCER. Cancer 1963; 16:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/66\">",
"      Berndt H, Wildner GP, Klein K. Regional and social differences in cancer incidence of the digestive tract in the German Democratic Republic. Neoplasma 1968; 15:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/67\">",
"      Barker DJ, Coggon D, Osmond C, Wickham C. Poor housing in childhood and high rates of stomach cancer in England and Wales. Br J Cancer 1990; 61:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/68\">",
"      Powell J, McConkey CC. Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites. Br J Cancer 1990; 62:440.",
"     </a>",
"    </li>",
"    <li>",
"     Nomura A. Stomach Cancer. In: Cancer Epidemiology and Prevention, 2nd ed, Scottenfeld D, Fraumeni JF Jr (Eds), Oxford University Press, New York 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/70\">",
"      Neugut AI, Hayek M, Howe G. Epidemiology of gastric cancer. Semin Oncol 1996; 23:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/71\">",
"      Stalnikowicz R, Benbassat J. Risk of gastric cancer after gastric surgery for benign disorders. Arch Intern Med 1990; 150:2022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/72\">",
"      Tersmette AC, Offerhaus GJ, Tersmette KW, et al. Meta-analysis of the risk of gastric stump cancer: detection of high risk patient subsets for stomach cancer after remote partial gastrectomy for benign conditions. Cancer Res 1990; 50:6486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/73\">",
"      Freedman ND, Chow WH, Gao YT, et al. Menstrual and reproductive factors and gastric cancer risk in a large prospective study of women. Gut 2007; 56:1671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/74\">",
"      Duell EJ, Travier N, Lujan-Barroso L, et al. Menstrual and reproductive factors, exogenous hormone use, and gastric cancer risk in a cohort of women from the European Prospective Investigation Into Cancer and Nutrition. Am J Epidemiol 2010; 172:1384.",
"     </a>",
"    </li>",
"    <li>",
"     Langman MJS. Genetic influences upon gastric cancer frequency. In: Gastric carcinogenesis, Reed PI, Hill MJ (Eds), Excerpta Medica, Amsterdam 1988. p.81.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/76\">",
"      Hoskins LC, Loux HA, Britten A, Zamcheck N. Distribution of ABO blood groups in patients with pernicious anemia, gastric carcinoma and gastric carcinoma associated with pernicious anemia. N Engl J Med 1965; 273:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/77\">",
"      Arid I, Bentall HH, Robert JAF. A relationship between cancer of the stomach and the ABO blood groups. Br Med J 1953; i:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/78\">",
"      Edgren G, Hjalgrim H, Rostgaard K, et al. Risk of gastric cancer and peptic ulcers in relation to ABO blood type: a cohort study. Am J Epidemiol 2010; 172:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/79\">",
"      Palli D, Galli M, Caporaso NE, et al. Family history and risk of stomach cancer in Italy. Cancer Epidemiol Biomarkers Prev 1994; 3:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/80\">",
"      Zhao L, Blot WJ, Liu WD, et al. Familial predisposition to precancerous gastric lesions in a high-risk area of China. Cancer Epidemiol Biomarkers Prev 1994; 3:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/81\">",
"      Hemminki K, Sundquist J, Ji J. Familial risk for gastric carcinoma: an updated study from Sweden. Br J Cancer 2007; 96:1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/82\">",
"      Dominici P, Bellentani S, Di Biase AR, et al. Familial clustering of Helicobacter pylori infection: population based study. BMJ 1999; 319:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/83\">",
"      Brenner H, Arndt V, St&uuml;rmer T, et al. Individual and joint contribution of family history and Helicobacter pylori infection to the risk of gastric carcinoma. Cancer 2000; 88:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/84\">",
"      Yatsuya H, Toyoshima H, Tamakoshi A, et al. Individual and joint impact of family history and Helicobacter pylori infection on the risk of stomach cancer: a nested case-control study. Br J Cancer 2004; 91:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/85\">",
"      Bonney GE, Elston RC, Correa P, et al. Genetic etiology of gastric carcinoma: I. Chronic atrophic gastritis. Genet Epidemiol 1986; 3:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/86\">",
"      El-Omar EM, Carrington M, Chow WH, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/87\">",
"      Figueiredo C, Machado JC, Pharoah P, et al. Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst 2002; 94:1680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/88\">",
"      Thye T, Burchard GD, Nilius M, et al. Genomewide linkage analysis identifies polymorphism in the human interferon-gamma receptor affecting Helicobacter pylori infection. Am J Hum Genet 2003; 72:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/89\">",
"      Zintzaras E. Association of methylenetetrahydrofolate reductase (MTHFR) polymorphisms with genetic susceptibility to gastric cancer: a meta-analysis. J Hum Genet 2006; 51:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/90\">",
"      Menetrier P. Des polyadenomas gastriques et de leurs rapports avec le cancer de l'estomac. Arch Physiol Norm Pathol 1888; 1:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/91\">",
"      Kinlen LJ, Webster AD, Bird AG, et al. Prospective study of cancer in patients with hypogammaglobulinaemia. Lancet 1985; 1:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/92\">",
"      IHRE BJ, BARR H, HAVERMARK G. ULCER-CANCER OF THE STOMACH. A FOLLOW-UP STUDY OF 473 CASES OF GASTRIC ULCER. Gastroenterologia 1964; 102:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/93\">",
"      Hirohata T. Mortality from gastric cancer and other causes after medical or surgical treatment for gastric ulcer. J Natl Cancer Inst 1968; 41:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/94\">",
"      Rollag A, Jacobsen CD. Gastric ulcer and risk of cancer. A five-year follow-up study. Acta Med Scand 1984; 216:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/95\">",
"      Lee S, Iida M, Yao T, et al. Risk of gastric cancer in patients with non-surgically treated peptic ulcer. Scand J Gastroenterol 1990; 25:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/96\">",
"      Hansson LE, Nyr&eacute;n O, Hsing AW, et al. The risk of stomach cancer in patients with gastric or duodenal ulcer disease. N Engl J Med 1996; 335:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/97\">",
"      Take S, Mizuno M, Ishiki K, et al. The effect of eradicating helicobacter pylori on the development of gastric cancer in patients with peptic ulcer disease. Am J Gastroenterol 2005; 100:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/98\">",
"      Take S, Mizuno M, Ishiki K, et al. Baseline gastric mucosal atrophy is a risk factor associated with the development of gastric cancer after Helicobacter pylori eradication therapy in patients with peptic ulcer diseases. J Gastroenterol 2007; 42 Suppl 17:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/99\">",
"      Brinton LA, Gridley G, Hrubec Z, et al. Cancer risk following pernicious anaemia. Br J Cancer 1989; 59:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/100\">",
"      Hsing AW, Hansson LE, McLaughlin JK, et al. Pernicious anemia and subsequent cancer. A population-based cohort study. Cancer 1993; 71:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/101\">",
"      Landgren AM, Landgren O, Gridley G, et al. Autoimmune disease and subsequent risk of developing alimentary tract cancers among 4.5 million US male veterans. Cancer 2011; 117:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/102\">",
"      Vannella L, Lahner E, Osborn J, Annibale B. Systematic review: gastric cancer incidence in pernicious anaemia. Aliment Pharmacol Ther 2013; 37:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/103\">",
"      Harvey RF, Bradshaw MJ, Davidson CM, et al. Multifocal gastric carcinoid tumours, achlorhydria, and hypergastrinaemia. Lancet 1985; 1:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/104\">",
"      La Vecchia C, Negri E, D'Avanzo B, Franceschi S. Histamine-2-receptor antagonists and gastric cancer risk. Lancet 1990; 336:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/105\">",
"      Colin-Jones DG, Langman MJ, Lawson DH, et al. Postmarketing surveillance of the safety of cimetidine: 10 year mortality report. Gut 1992; 33:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/106\">",
"      M&oslash;ller H, Nissen A, Mosbech J. Use of cimetidine and other peptic ulcer drugs in Denmark 1977-1990 with analysis of the risk of gastric cancer among cimetidine users. Gut 1992; 33:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/107\">",
"      Klinkenberg-Knol EC, Festen HP, Jansen JB, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994; 121:161.",
"     </a>",
"    </li>",
"    <li>",
"     Guidelines from the ASGE available online at file://www.asge.org/assets/0/71542/71544/db54732efefe4808b65e317ea6e4e5ee.pdf (Accessed on January 29, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/109\">",
"      Schorah CJ, Sobala GM, Sanderson M, et al. Gastric juice ascorbic acid: effects of disease and implications for gastric carcinogenesis. Am J Clin Nutr 1991; 53:287S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/38/618/abstract/110\">",
"      Parsonnet J. Helicobacter pylori and gastric cancer. Gastroenterol Clin North Am 1993; 22:89.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2617 Version 23.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-3399DFF423-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_38_618=[""].join("\n");
var outline_f0_38_618=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRECURSOR LESIONS FOR INTESTINAL TYPE CANCERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Atrophic gastritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Intestinal metaplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Dysplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PRECURSOR LESIONS FOR DIFFUSE TYPE CANCERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ENVIRONMENTAL RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Diet",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H367054345\">",
"      - Salt and salt-preserved foods",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Nitroso compounds",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H367054797\">",
"      - Fruits, vegetables, and fiber",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Folate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Obesity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Smoking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21378716\">",
"      Helicobacter pylori",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21378723\">",
"      - Influence of salt and intake of salted foods",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21378730\">",
"      - Possible protective effect of NSAIDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21379094\">",
"      Epstein-Barr virus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Alcohol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Socioeconomic status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Gastric surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Reproductive hormones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      HOST-RELATED FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Blood group",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Familial predisposition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Hereditary diffuse gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Genetic polymorphisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Gastric polyps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Hypertrophic gastropathy and immunodeficiency syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Gastric ulcer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Pernicious anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      INTERPLAY BETWEEN HOST AND ENVIRONMENTAL FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7442988\">",
"      SCREENING GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2617\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2617|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/45/4817\" title=\"figure 1\">",
"      Parts of the stomach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2617|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/24/17802\" title=\"picture 1\">",
"      Gastritis intestinal metaplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/19/10547\" title=\"picture 2\">",
"      H pylori in gastric pits",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2634?source=related_link\">",
"      Association between Helicobacter pylori infection and gastrointestinal malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/16/43271?source=related_link\">",
"      Bacteriology and epidemiology of Helicobacter pylori infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/0/5130?source=related_link\">",
"      Diagnosis and treatment of vitamin B12 and folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/35/4661?source=related_link\">",
"      Epidemiology of gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26184?source=related_link\">",
"      Epidemiology, etiology, and diagnosis of nasopharyngeal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11786?source=related_link\">",
"      Etiology and clinical manifestations of vitamin B12 and folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/19/2361?source=related_link\">",
"      Gastric polyps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2296?source=related_link\">",
"      Hereditary diffuse gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/58/2984?source=related_link\">",
"      Large gastric folds: Hyperplastic and nonhyperplastic gastropathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17418?source=related_link\">",
"      Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24185?source=related_link\">",
"      Metaplastic (chronic) atrophic gastritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/33/30234?source=related_link\">",
"      Molecular genetics of colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25034?source=related_link\">",
"      Overview and comparison of the proton pump inhibitors for the treatment of acid-related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/26/33194?source=related_link\">",
"      Pathology and molecular pathogenesis of gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/34/3625?source=related_link\">",
"      Prophylactic total gastrectomy for hereditary diffuse gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/52/6983?source=related_link\">",
"      Screening and prevention of gastric cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_38_619="Quick sources of sugar non-diabetes PI";
var content_f0_38_619=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F67760&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F67760&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Quick sources of sugar to treat low blood sugar",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        3 or 4 glucose tablets",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &frac12; cup of juice or regular soda (not sugar-free)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2 tablespoons of raisins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4 or 5 saltine crackers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 tablespoon of sugar",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 tablespoon of honey or corn syrup",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6 to 8 hard candies",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    These sources of sugar act quickly to treat low blood sugar levels.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_38_619=[""].join("\n");
var outline_f0_38_619=null;
var title_f0_38_620="MEN2 genotype timing progression";
var content_f0_38_620=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F58578&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F58578&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    RET mutation-related youngest age of onset of MTC",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" colspan=\"2\">",
"       Age-related progression of hereditary MTC depends on RET genotype",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       RET genotype of MTC",
"      </td>",
"      <td class=\"subtitle2\">",
"       Youngest age at first diagnosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       918",
"      </td>",
"      <td>",
"       9 months",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       630",
"      </td>",
"      <td>",
"       12 months",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       634",
"      </td>",
"      <td>",
"       15 months",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       609",
"      </td>",
"      <td>",
"       5 years",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       620",
"      </td>",
"      <td>",
"       6 years",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       804",
"      </td>",
"      <td>",
"       6 years",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       611",
"      </td>",
"      <td>",
"       7 years",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       618",
"      </td>",
"      <td>",
"       7 years",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       790",
"      </td>",
"      <td>",
"       10 years",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       891",
"      </td>",
"      <td>",
"       13 years",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       912",
"      </td>",
"      <td>",
"       14 years",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       533",
"      </td>",
"      <td>",
"       21 years",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       791",
"      </td>",
"      <td>",
"       21 years",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       768",
"      </td>",
"      <td>",
"       22 years",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       666",
"      </td>",
"      <td>",
"       35 years",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       649",
"      </td>",
"      <td>",
"       44 years",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: de Groot JW, Links TP, Plukker JT, et al. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr Rev 2006; 27:535.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_38_620=[""].join("\n");
var outline_f0_38_620=null;
var title_f0_38_621="Urea as an ineffective osmole";
var content_f0_38_621=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F53067&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F53067&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Urea as an ineffective osmole",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 414px; height: 309px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Effect of adding a permeable solute such as urea to the fluid on one side of a membrane that is permeable to water. In this setting, equilibrium is reached by urea equilibration across the membrane rather than water movement into the urea compartment. Consequently, no osmotic pressure is generated (estimated from the height of the column of water above the urea compartment).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_38_621=[""].join("\n");
var outline_f0_38_621=null;
var title_f0_38_622="CT hepatobiliary disease";
var content_f0_38_622=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F72112&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F72112&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Computed tomography of hepatobiliary disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 349px; height: 326px; background-image: url(data:image/gif;base64,R0lGODlhXQFGAcQAAP///39/f4CAgD8/P7+/vwAAAO/v78/Pz9/f3y8vL09PT19fX5+fn6+vrx8fH0BAQMDAwG9vb4+Pjw8PD+Dg4KCgoGBgYLCwsHBwcNDQ0CAgIDAwMJCQkFBQUBAQEAAAACH5BAAAAAAALAAAAABdAUYBAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fm+jCP6AgYKDhIWGh4iJiouMjY6PgBR8cRAOAZeYmZqbnJ2en6ChoqOkpaanAQ4Qk3AQA6xuA6uwba60bLK3bLa6abm9abzAZr/DZsLGY8XJY8jMYMvPYM4iDZcHVgEDDCMM3CkHEQAICCzeJtYBBwYE7e3YQOQy0dJe1BEKBAwDBFQMCgAMjLikgsCrcysIkhiwgECDbZccLAjw7QdCGPTqcaFWgITAAwoGNBBBQIGCAOUC/5DsB0DbAoEOF/CrNkDBSJAiSxjQFkDggAEoB0aQyRLnSIMA2gWUGYFdyJctVY6QsMCjiJklcEp9aBNAhJ8jWz6sCoBBA5PllJpFK2LfRBMZNWqhVrNBuXEJEBjgh8CB3gT9Okb1qvJhywEIDjgA0CCBAQQMEOTdy1LE2wBVFzQUKEJb4sWS9fJDSjABtwYHDpSjOnhETriVR0xYJ4GxY8iMA/oFUICbAm4DmrImGNwA67OPBS+cJdfeK50SFDhwLAEoTwniAMwUTHACpo4KO3YVUf0SUBITZLceKLVjeZ6k1SXwGD3BK4VXY7vWD8BBBAICjUfSVxME1plKM8WnXf8/SI2nnGvMNbfRcyhMhJk7CCi03YG8udNPeAsO1FA7d4mgHHhSsWdiSyMSgEB8SI2QgATs3JciAAvUBpsJxikwAWUjNIbNhoMlaGOISGH14FURSjgXhVON8BsBDnB2gGEAAAbAjzgiqCM2IGImwgFUWklCVyWtxyFvSVU5ZnwGTFBOcgLtoyaVdxEAD1YksASYmAAcEIA4BmjJHYIMHmkkYQEtqV2TTmJBzQIODJCAVAzYl8BIESRAaT8SVHpSQAokkABAIBqwgH0qZWppWGP+NACYN7YmmKubKtjYT5BVKpOatv2kwF18SmkqoasCVWhNhnK4KHGJBvRTBI7GFSn/FdRgxN+1MXDWF1yQcostlPNsK64LilkKz3LnSkpuu1FYC28T2c7bhLz2KlFvvkrgy+8R+/57hL8CExFwwUQQjHAQBy8chMIO+9BwxD5ATPEOlaCi8cYcd+zxx6eocnESfkBi8sko//HAAym37DIjkows8B8y1+wGzTbnnAbOOvdMBs8+B/0F0EIXrQXRRiddBdJKN+2EBgVEXYAHTlfthAVSF9CB1VwrUUHWHHQtthEUZJ3B2GgPsUHUGqTtNhAYRG3B23TzcEHUFdStdw5Rx7z33zM8sAHghMsgAAaFJ+5CBhco7vjjkEcu+eSUV2755ZhnrvnmaFTw8ueghy76/+iN5E33AxaCrPrqrLfueigLPFD3A+ZaToDsp9de+e2z604577lzThLub9MufFLEu2288MAX7/vkzSv/vOTRp738CGQCeIIB67bAPQ7aVKQFAhIEsC0BmIivwvclNDA9CtWjfX1bEpVIQjgsxIi/Df8EVEOxLcAP/N4VAQYQYFMmuJCeXBAjEjimBvEb2/zy05mxjIMiNFEAPLhiDUu4iBs7UVZSGkAUnfDEJ0Cxn0uw4ZZyQEYbtenLZTIEmZ9sBSzaSeEIECATDbbEgyeIgI5IIEAiPqQpJWygCHjYmZpgQ1XnCVRIhji83u2IN75hgHFegZy+GKAxj/EGYF70iv/LVMUziimBGXG0mREMJVAN+Ac7FkMlAPmlUBIITAq19xvFhJGN2lsiNtKYKReVAAFD4QwRK9WTEvQGAGhJoxK9MpLowDFL/YgAShxAmxJEUGwTDBGbBtMgCzmgJLCKEVLSI4L0gAg96ikil0SQj6uQ6TkzUdIOtWEJBEwgj2siAQNk0pFJiqBGI9nHNsaxlOyM4FArmuRzMsWAQVoCMwPADvySZz3+6JKUr8imO4BEkucg5US2cuQzgfUgrIwGl/34Zl9GQpAM2QdYQylHMd81AmP2k1zQZJMSG+BMAkTAg4B5RxH7yU35eZMl0CQNQAKSIbKQaT5JeQWaUNWeEmz/FFjLDJQ2DUBHeGonLII5oGVQMifwOPMqI0FAMTHap86QpaYteekoQaTEBdxlHYwZQJzgQabFBMqTDZWgfiIwgQRgI6LP6ZSl9JIsBG0DKQeQFa1WdD+tAiurYFGVqY5i0l2NEkf2OYlkLMWNta4rXdS6SkhpaSoFKHIgdb3rTjtKgAnIqoG7cmqgNKWSAKQVqVZ8AZZ6xgAq0uCTXQtlChLgAFjprAF6nQFkuSbZy23Wap21XVJB+T7IfbZqod3daCNb2sed1mmp/d1qOdtax722abGF3mxBm7rX+fa3wA0u7HZbNc+R7rgvWxlyl9sy0x1PDEx77tiiK92uUbe6/1a7Lnadpt3tKq273jUaeMPrM6hJjWrkrRrWpLa19Drta1ILm3ubVjapnW2+TVtbAdqG36bFrQBz66/S7lYA5wrYaH07sNIEp+DvIq7BRmMchCdM4Qpb+MIYzrCGN8zhDnv4w4+DAHNHHC4qGHfEKE5xIgwcBwFYR7ivG4AAtoA6GNv4xp6IXR0EUCsxBGDGWsjttW57Bh6f4cc0rq1ciGwGI5sByUFWskaYXAYnlwHKWRBypKj8sx6HActY0LKTuDwGK5MBzFcQs4TIDF0vgwHNVlBzc9gcBjOPAc5VkPOSibszN4/AAAwIAKwCfQn+WING3TAfEPBMhQmyL1CZjf8BUIMw6RLwU5jqk8EBMo28HfuZPHmMojgN2af/SACjF9KSDxg9BA90gAP3VcEEGwhAFygkAt2DgaOCmGuupmChL1AVdv6DWDrYOQUxqrVOWJmXsuhUGz6EolSg2BQVsFoIWdOABSrgtxLMmkIzkXZbzmLXsthQriiJjBSzSQIeOnEcBjRfATBolM7QUN1fec2S1lLuQZXQ3dGWCVTqPQ4HFIA/dAbDsVEAKEvNtQT/QGk5SWDJK2GSUaZhTK+JyDIV/yFrWdsABhpHgllfMxX90JImtSMOS/KRG5oBEF84aZx2WzMpE1DrwVUzme2kcCYjIak+Ld1yVCEmjYkJ1GL/FFAb1ISGMsKOALH7xGc0LNwEflwiXkYiK+xliqtKpKY1LyGTA9A0IR33OMilxrJYi2DWCT2gnq75K11maACWaA0/tHmCYQ5gn+sEwHvOo5wEEchAC4FoOstCTBzZZDXWieKmT5DwoX16TJxMoJ9nwso0lRqh7rilrYGchJCPPAXf3o/c3yHKAsxzMBpCn5fzKVAKcadFQ8+PkEK0JF2CiPa3WkCBFEhqZFe9yJdXTPdY8hrsCSRO5eiKEO8nkIcMdUzQp6i1SY8EbXObBanPz/WPCvR8YPQy2RmNUbuXE5lm9JkwcdNRC48+QjUr8Yzh6IraX0wRaLJMY7IClecF/1fnGpXyE3SVADoVLBk3WD9xV4E1SIQVLIixfUnmSeDWD2ZnKQhiH7OCVjWhEm41E4ZVE/dTKXHVQIYlDrgyEvS3LKWCeK7hgVvFJnAFHh5YJ5piWZR3fE12eVxwbVGgZ6L0Bcr2AwPYBQXoBUIIBUR4hFkAhT2QhFywhF3QhE9AhPVAhVtghUHIfWkmZVvog1UGhFuAhU6ghdLAhUdjhlqAhk2ghs/AhlnghWcIhnEmhmtIhl12ZHiYZ3o4h3xYZm6YBXDIBHLIDHSIBXb4hn/YaIGoiIMIXS+GY6ojYzTWW5a4icKlY3QgYsilXMtVYlNwYh53iqfIYuIyXiC2iv+P2Ir2woqwGCmyOIsSUou2KBe4mIv1sIu8mAzmFTXo9Yvnsl5R017EKC7wFTXylYzcUl9R43bOGCn6xV/TyC3/FWDXeC0Eporb2BwJ9o3XwmDieC2HU47XImHouI7s2I7u+I7wGI9oA4qoCDqkOAX0WI/6aI984GKceImvOAX++I8ECTKYuAeNaIgBKQUJmQyHyAYNeQUPuQQROQwTqQYVWQUXmQQZ2QsbaXWFiAUfeQQdqQsj+YN+WIUhaQwnWYYp2YUraZEL2WIxqZEzCQUleQst2YdPdpNPkJO0sJOE2ALWwBLGERSH5CF3EWiR+Gs+6QTH9iILVAP7AwUX0QP/QtlmLAAUU5lNDSB//YQJ55FqTXkCWRkEx8YTCnBTA9SWUQBsOXCWCnd5w+QRRrUAPEgCu9FsDPBs7yZuS1EcFqgErgZrLZCWUgEYIdRI7eANqWA+AIcNA8USDhFUPvRC7JYUJsESUqEUWgFx5CYQ/jYTkRmYAxcSeZlAT9kGVriWNREtwCIiYAclFTcSKqcSGYcag1l6UuN93VYCiCkCnLRGATABBVRI5HBzYTdRv9FFVVJHQtcX5LAb0DQbNbcQRXcYnzEON8d0Gvd0M8EAE5B5JSCXlrcC7OZHMUIcCHhMcjKbwmQaY4dNZmdraadiaxc1IkdyJJCWQMEQWxJL/51JIX4HeOgxnZBkSu0AT+XTGbUBTf4RSPuxIq9UoI5nF4IXeSoxAVEzUUS0mhB5ee6kJ88RAI5lU+qhmZ50UOYTd6IXQPeZYvlZAG1nAmnZEHeBTgoRI8D3fkRkol4yTskmexwCTT0ySxTEJr/nU6M0TMOHe/0RNWzZGSC6BlbIGnEiEFwiWMtWItJHRUBlfbOBfe/5GLuJBKbHnycQnFJyFPqXFBjFfz66Qw6wGwEwUY8xpPWpHdjAJW/hJ7FRfukkpyzxf/I3SGuZWeZJgEAoVd+QKQpolmy5gUJFAhHogJdCgfajmkvgm4fZYwIEVh+IHz9RTShooGdyU1KVF/9D2hKmIhWhEoKQdCyWRoPpdIOu+oBlsYMJUaUYWZNUsKg9AJRXIIU8IKwq+ZJtGAtlGUC+2mfKWofAapLPCpLRyojTqpPVinzXegXEygrICpPdagXfOgnhuqw9mazncq7SOq5Lk61Bua0oma7iuq7y6pL0iq7iwq6MWIkFqTEHeTT++q8EWwoBmwf5ODqiiFz3KAUJu48QizINey6+KI87dq8WCwcVm7FysLEcq7EY+7EQGbIii5EkW7JmEIxTg7KsYIxaw7KTsIwF0IwwmwfQWADSWLN3UI06ywfZ2LN70I1AuwfhOLR4QI5GiwfnmLR4oI5M+7RQG7VSO7VUW7X/VmswEesyEwsFD5u1XjsIW6u0A1uwpHCw/Uq2aLsJZksL5doE/HoDbSsHb3ue+dquGjG3jOquVBC3cYC3SgivUOC3M8C3cCC49XplJwsEhPsGhquvZ5a4P7C4btC4dou46loPlIuteiuQgFsHmeutlwdoGPQCzeqsl9snocdAgSIO8oBrKPBoOOC6NsAOTjkMV5pHC7CAKXBpmncDhluYObumXjZvl8BpJ/AKSHEOR1iVOGCsLMBUqdkSkMutROmh42YSIaQjIhho7IYbZVEONpQSDFF9OHSmR5Bt2/ab/Tm8hyQTiqZu3qsSSKEUQIG9SaEPkcEN8NtW3FtNbGFE/8FxFdExLJo5vut2Qz7USnfKcNM7rwmRwK4hHIpJnW1iR2REQTFnACv3EH7kvb8Woyg2o/tpo8ObPv3RD2+xKLVXJCphScVZQEkSLdBpCcYxpQUwEt5ZHKyhGoJXFdbZdHblRfmXpWbZwPgqgFJnabC5IUPaqgrhHZfger/0PAEAwiM2ozUKnMMbensKLT4KeF6spAOKJMhrUpOUUuEULT1yTxEaIAoKSTB3otJru4XYe0tsIE1sUuHhIRd0T+ZrBGmqAgv3IOuJKF/8fmGMIhO3KK16xoscLTNSIwERHT8yagBCxCrFqcBghZRpVBPaqgbKD/VZKB+Sfl8iDwawa/8f2qnp+6kn8CBEvHJdYScr7MVn0RoNkkxlTEGO7BW1sSgFUCfIKwJ/gqfkc1PkucqbfHklyKWfbFKh3A+lEoN4MSsGUCqnslYNWLuHSwIFICsseCrnQSUM8Rxg3IE/UYPz6yu7TMaOZClQsSgMwM6zGqleoSmScYADYJya3AuSewSf68ovAJellwQB/a6by5AhSdBoatBGzJOW283PcNB727lOQNGCbNFzgNEKndBR8M9swNEfrdFMINLCKxcm/ZMkvQQprcUo/dBDWbeae7cwrZUyDbovTccejZMrXbg1XWdjm7agsLbkGtRCXZBEzQpdCzoLe1xh6wRL/bVS/dT/+eKxV8uIP33VHJnVWk2SXN3VRWDVYC2QXz3WQiDWZv00WTOMaR0GLouMbQ0GMkuzce0FNxu8db0FPJvXYfCzfA0GQvvXYFC0gt0FSFvYSvhgiN0FTrvYjv3YkB3Zkj3ZP1AyUk066vsEUX3ZTi0hGXPUqyMye2vUoL06SZ0ME3MGFhPWPf0FLX0FqU0MVM3a5lrWx8C7a7DaRADSd+jZuK0Guj0EvO2Ivk0HwX3Wrc2Etl0GsV0Gx42WyX2Fy00GzU0Gz6240f2FxT0H1x252d3bzVEvyze6J6AX7HEJmwoOkaYD3e0DUekOKiC7NPDbzPsDr20F1AAZyiF3b6ET/19ZGQfXDuttAvJdEL99vLN9A8CbAv45KNusxDagyv+UA7Vz31VADeijHAWEFyaQIacUeB3evyBBwOomaAD6vfD2Q4rGFU8kcHrV3rrWm628vr0bEFoCmDORbyPhPiSx4+9mbguwJDHxgQYBQ/5XvtDW4lFkGQ+nzHJRL/TnaxBuIq/pSadEUj3BGtuRRe6MnM55zU2XawNgAfiZnyMMAGxaFgBxmyESdH6BJSLx5V20JNrAPekxw+Xg5uQDEBbH5jgCc5xm4eOCAlHOJspUEXySFrsx4e5MJF48v8+xlhFBAAvweHBB5jKan1mc5gahGGSXxklxeP2BoJKOcg5Snv9S8U68fHhip3Sf/ucjsACZJuj4eGnKUUsBerwP1SdmDOrQxMi4lEcCzngFYmkJHuFSc+Y0jurd8B8uuiC7NxNUMX2WTE50nuoLqnuCZXigx3p1KS29RusOa+tTIQ63rOtLNCdI6qOL4ugqMcvIi2rGXKi1AuMv4KkowKaKoRdjSn71Z+P9QFJussAUtXKpzOxxwu7/TsphKlT9Dg/DtBcbJ+5RQA378M0g9BPOjD37HKnarD6N7OscQs6/kkPcsKr2pKvsUtEJVCmnQlQTyA8wqGq560b4vBdAQecuT1bil1aAcakbmKn0s3FzHN4Hjgb2vgOEu+gwwNA1MOAUz7WTR6/ax47cPfDtMeD0qzbdzTD1so3QfBD1mu31zl310F3b2y0HSa8Dw62QaR8Ha58DbS+SXC8G1a0MZo/daG/0xp333r33T0721u337v3dxM333E34w2r4bh/eJ1faHiPaAknakP8xp20Mls3ZoZPZUK35Kqb4lB36oj/6pF/6pn/6qJ/6qr/6rN/6rv/6sB/7+BUCADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Heterogeneous enhancement of spleen and kidneys (cortex &gt;&gt; medulla), dense opacification of hepatic artery, minimal enhancement of liver and portal vein, in addition to non-enhancement of hepatic veins may be seen on an optimal vascular phase image.",
"     <br>",
"      &bull; Dense homogeneous enhancement of the liver, spleen, and kidneys in addition to opacification of all large abdominal blood vessels constitutes an optimal portal phase image.",
"      <br>",
"       &Delta; Homogeneous enhancement of all abdominal viscera with excretion of contrast-opacified urine by the kidneys constitutes an optimal equilibrium phase image. May be helpful in distinguishing HCC from regenerating nodules and dysplastic nodules as some carcinomas will have a discernible capsule at this stage, whereas regenerating nodules and dysplastic nodules should not.",
"       <br>",
"        &loz; Tumors with a large component of fibrosis such as cholangiocarcinoma demonstrate prolonged hyperdense enhancement.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_38_622=[""].join("\n");
var outline_f0_38_622=null;
var title_f0_38_623="Proximal wasting in Cushings";
var content_f0_38_623=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F64072&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F64072&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Proximal muscle wasting in Cushing's syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 208px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    37-year-old man with Cushing's disease who followed a rigorous diet and exercise program. There is no overall weight gain and minimal centripetal redistribution of fat; however, proximal muscle (deltoid) wasting was evident.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Williams Textbook of Endocrinology, 8th ed, Foster, DW, Wilson, JD (Eds), WB Saunders, Philadelphia, 1996.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_38_623=[""].join("\n");
var outline_f0_38_623=null;
